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ABSTRACT  
Natural killer (NK) cells are innate lymphocytes that play a role in infections, tumours and 
transplantation. Their activating and inhibitory receptors sense cell surface ligands on potential target 
cells. Increased levels of stress induced activating ligands and decreased levels of inhibitory MHC 
class I (MHC-I) ligands cause activation of NK cells. NK cells are “educated” to tolerate self, and the 
“rheostat model” proposes that this is a reversible and quantitative process, where the degree of 
responsiveness acquired by each NK cell is proportional to the amount of perceived inhibitory MHC-I 
signals. Assuming that the NK cell integrates MHC-I input over multiple cell encounters, education 
may also depend on the ratio between cells with and without a critical MHC- I ligand, e.g. in 
chimaerism after haematopoietic transplantation. This thesis addressed how NK cell education is 
affected by perturbed sensing of MHC-I, and how the process is influenced quantitatively by the 
frequency of cells with a given MHC-I ligand. “Allele specific” as well as “general” missing self 
reactivity (targets lacking one or all host MHC-I molecules respectively), against normal and tumour 
target cells, was analysed. 
     The DL6 mouse strain presents a mosaic expression of an MHC-I transgene such that each cell 
either expresses it (Dd+) or not (Dd-). To test NK cell killing in vivo of two different targets in the 
presence of a control cell population in these mice, one aim was to develop an assay to measure 
rejection of three fluorochrome labelled targets in parallel. Using this assay, all mosaic DL6 mice 
were completely tolerant towards normal Dd- spleen cells (“allele specific” missing self), even if they 
had a relatively high proportion of Dd+ vs. Dd- cells. There were varying degrees of impaired reactivity 
in the mosaic mice upon challenge with MHC-I defective spleen cells (“general” missing self), with a 
moderate inverse correlation between the number of host Dd+ cells and the survival of these target 
cells. Tolerance towards Dd- RMA tumour cells representing “allele specific” missing self was not 
complete; partial rejection was observed in many DL6 mice. There was a weak inverse correlation 
between the number of Dd+ cells and the survival of these target cells; in particular, there was an 
efficient rejection in all mice with >83% Dd+ cells. The frequency of Dd+ cells did not influence 
rejection of MHC-I deficient RMA-S lymphoma cells; all DL6 mice rejected these cells efficiently. In 
chimaera studies where Dd+ bone marrow was used to reconstitute mosaic DL6 mice, there was again 
complete tolerance towards normal Dd- spleen cells, indicating that a fraction of ligand deficient non-
haematopoietic cells is sufficient to induce tolerance to normal cells of this phenotype. Again, the 
results differed when tumour cells were used; there was significant (but reduced) capacity for “allele 
specific” missing self rejection in these chimaeras. In the reverse setting, mixed bone marrow 
chimaeras were constructed in which different ratios of Dd+ and Dd- cells were transplanted to mice 
with normal Dd expression in the non-haematopoietic compartment. Significant but reduced capacity 
for rejection of Dd- RMA tumour cells was observed, despite apparent tolerance towards normal Dd- 
cells. Finally, when MHC-I sensing by NK cells in B6 mice was perturbed by treatment with 
antibodies against inhibitory Ly49I/C receptors, it led to impairment of “general” missing self 
reactivity towards MHC-I deficient spleen cells, despite increased killing of MHC-I expressing RMA 
tumour cells. Both changes occurred within 24 hours after inhibitory receptor blockade, and it was not 
possible to separate them in kinetic studies. As in the DL6 mice, efficient killing of MHC-I defective 
RMA-S cells and tolerance towards normal MHC-I expressing cells, were preserved. 
     The results show that tolerance develops robustly towards normal host cells lacking one MHC-I 
ligand, i.e. the Dd- cells are critical and dominant tutors in the education process even if they are in 
minority. A model is proposed in which the education sets responsiveness for each NK cell such that 
tolerance is ensured towards all normal cells in the host. This occurs via multiple cell encounters, and 
results in a reduction of responsiveness in certain NK cell subsets with inhibitory receptors for Dd 
molecules, correlating with the proportion of Dd- vs. Dd+ cells in the environment. This Dd+ cell 
frequency dependent, quantitative educational effect is revealed when using MHC-I deficient spleen 
cells or Dd- tumour cells as targets. A similar interpretation is offered for the results observed in 
antibody mediated inhibitory receptor blockade, where the perturbed MHC-I sensing is manifested as 
a reduced inhibitory signal from all cells to certain NK cell subsets, rather than complete lack of 
inhibitory signal from a fraction of the host cells. The results are discussed in the context of testable 
experimental predictions of in vitro NK cell responsiveness in mice with mosaic or chimaeric MHC-I 
expression, as well as in the context of implications for clinical immunotherapy against cancer. 
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1   INTRODUCTION  
1.1   BACKGROUND    
The immune system is a defence system composed of a network of cells, substances and 
tissues which coordinate to protect the host from foreign invading agents or internal 
anomalous changes. Its essential features include mechanisms to detect foreign or altered 
components, to communicate within and among different arms of the system and to elicit 
responses by various fractions of the system. Conventionally, the immune system in higher 
vertebrates has been divided into the non-specific innate section and the more specific 
adaptive section. The innate immune system constitutes the first line of defence and 
comprises mostly non-specific mechanisms e.g. mast cells, phagocytes e.g. granulocytes 
(neutrophils), macrophages and dendritic cells, eosinophils, basophils, natural killer 
lymphocytes, complement system, antimicrobial peptides, anatomical barriers, etc. Pattern 
recognition receptors are also included in these, of which, Toll like receptor family is an 
important type in recognizing pathogen-associated molecular patterns. The adaptive immune 
system forms the second and more efficient line of defence as it retains memory of previous 
antigen encounters. It consists of T lymphocytes, B lymphocytes and antigen presenting cells 
e.g. dendritic cells, macrophages, etc. However, with advances in research, considerable 
overlap and cross-talk between the two types of immune systems is being seen, thus the 
division is seen as more labile. The studies presented in this thesis pertain to mouse NK cells 
and, therefore, general characteristics of mouse NK cells are described in more detail in the 
following sections, while human NK cells are mentioned briefly for comparison, and 
sometimes in detail when there are interesting differences between the species (Table 1).  
 
 
 
 2 
1.2   NATURAL  KILLER  CELLS    
1.2.1   General  background  and  biology  
Natural killer (NK) cells (reviewed in [1]) are important cells of the immune system. 
Although mostly categorized within the innate component, there are studies showing their 
role in the adaptive immune component, and as bridges between the two systems [2, 3]. NK 
cells are generally conserved across species albeit with changes in surface proteins [4]. They 
play an important role in controlling viral infections and in anti-tumour surveillance and 
responses. They also partake in pregnancy and graft rejection (including graft versus tumour 
effects).  
NK cell development is independent of thymus and gene rearrangement in their receptors, 
which are germ line encoded. As components of innate immune system, they bypass the need 
for prior stimulation, unlike T and B lymphocytes, and elicit effector functions upon primary 
exposure to the target, spontaneously mounting killing responses to targets and thus, earning 
the title ‘Natural Killers’.  
NK cells communicate with surrounding cells in several ways. It could be via soluble 
substances, which act on cells independent of cell-cell contact. Upon contact with a target 
cell, they may form an immunologic synapse. After moving away from target cells, they may 
also maintain contact with them at distances via nanotubes [5]. Different pathways are set off 
as a result of these interactions. NK cells are capable of producing lymphokines, mainly 
interferon (IFN)-γ and tumour necrosis factor (TNF)-α, and causing cytokine induced cell 
damage. They also show direct cytolytic activity via release of cytotoxic granule contents, i.e. 
perforins and granzymes in target cell proximity, which leads to its apoptosis. Another 
mechanism used is Fas-Fas ligand induced apoptosis (Figure 1A) [6]. With respect to these 
effector mechanisms of cytotoxicity, NK cells share many features with cytotoxic T cells [7]. 
Major differences between these two cell types are a) T cells must mature and undergo 
quality control in the thymus, b) T cells require antigen specific activation and clonal 
expansion in lymphoid organs, before they can become cytolytic effector cells. Some NK 
cells may pass through the thymus, but most mature independently of the thymus. 
Furthermore, NK cells are present as cytotoxic effector cells in blood and tissues. They may 
need regular contacts with dendritic cells to remain primed for cytotoxic action, but they do 
not require proliferation and clonal expansion. The two effector cells, therefore, engage with 
different kinetics during immune responses (Figure 1B) [8]. NK cells act immediately and 
their number as well cytotoxic function can be augmented within 1-3 days. Cytotoxic T cells 
require 4-5 days before they can act [9]. NK cells may interact with other components of the 
immune system in a regulatory capacity as well [1, 3, 10].  
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Several other innate lymphocytes (ILCs) have been discovered recently, defined as a group of 
lymphocytes lacking receptor gene rearrangement. Mostly tissue-residents, they do not form 
a major part of the peripheral blood lymphocyte population. ILCs are activated by cytokines 
and activating receptors and take part in early responses in infection, allergy, autoimmunity 
as well as in tissue repair. Due to their interactions with other immune cells, especially via 
cytokines, they also have an immunomodulatory role [11]. Based on development, phenotype 
and function, three main groups of ILCs have been identified. NK cells belong to group 1 
ILCs and share certain features with other ILC1s, especially regarding roles in inflammation 
and infection, but they are developmentally distinct from each other [12]. 
1.2.2   Morphology,  distribution  and  cell  surface  phenotype  
Morphologically, NK cells have a high nucleus to cytoplasm ratio and other features making 
them indistinguishable from other lymphocytes. They may, however, have large azurophilic 
granules in their cytoplasm, which contain cytotoxic substances [13], hence, the 
nomenclature by Loughran in 1985 i.e. large granular lymphocytes.  
NK cells are mostly found in peripheral blood, lymphoid organs and to some extent in bone 
marrow. In physiological conditions, they have been seen to locate to medulla and paracortex 
of lymphoid tissues but may move to maintain contact with dendritic cells or come in 
proximity with T cells [14]. In humans, circulating peripheral blood mononuclear cells 
contain 5-15% NK cells. In mice, NK cells are usually isolated from spleens where they 
compose 2-5% of the lymphocytes. Several tissue resident NK cell populations have been 
identified and although they share properties with circulating NK cells (of the bone marrow 
(BM) origin), they may represent NK cells from a different lineage or progenitor (for 
example liver NK cells) [15, 16].   
Figure 1. General NK cell properties. A: Diagrammatic presentation of some central NK cell 
effector functions. B: Schematic presentation of kinetics of NK cell and T cell responses during 
a viral infection.   
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Like other cells, NK cells are identified by surface expression of protein markers many of 
which are classified as cluster of differentiation (CD) markers. A general classification of NK 
cells in humans is CD3-CD56+ cells while in mice, CD3-NK1.1+, CD3-NKp46+ or CD3-DX5+ 
is used. NK cells are then further classified phenotypically into specific subsets or maturation 
stages, depending on the research question under investigation. The details of these markers 
are discussed in the following sections.  
1.2.3   Development  and  maturation  
Similar to the other innate lymphoid cells, NK cells originate from haematopoietic stem cell 
(HSC) precursors. The bone marrow is the main site of NK cell development in the adult 
mouse. The common lymphoid progenitor (CLP) commit to T/B cell or ILC lineage prior to 
antigen specific receptor gene recombination. Under the effect of transcription factors Nfil3 
and TOX, the CLP passes to the ILC/NK cell precursor stage. From here, the expression of 
GATA3 and Id2 transcription factors mark its commitment as the ILC precursor, which gives 
rise to ILCs. Group 1 ILCs rely on the transcription factor T-bet for development and produce 
IFN-γ [12]. The ILC-2 group is characterized by interleukins (IL) -4, 5 and 13 production and 
dependence on GATA-3 and RORα transcription factors. Group 3 ILCs require transcription 
factor RORγt and produce IL-17 and 22 [11, 12]. From the ILC/NK cell precursor stage, a 
pre NK cell precursor develops, which under the effect of transcription factors Eomes, T-bet 
and Id2, passes through the NK cell precursor and immature NK cell stage, and later 
completes development of NK cells in the periphery. Transcription factors T-bet and Eomes 
provide two checkpoints for NK cell maturation, especially in the BM medulla [17, 18]. 
NK cells undergo several developmental stages in the bone marrow, defined by surface 
markers including CD122 (IL2Rβ), NK1.1 and DX5 [19]. These stages correlate not only 
with surface marker acquisition, e.g. receptors, but also with functional capacity. Together, 
both confer education and expansion to NK cell clones. The NK-committed progenitor 
called pre-NKP, arises from the CLP and lacks IL-2Rβ (CD122) [20]. The CD122+NK1.1– 
NK cell precursors or NKP, previously thought of as the first NK-lineage committed 
precursor [21], give rise to NK1.1+ DX5- immature NK (iNK) cells and DX5+ Ly49+ 
mature NK (mNK) cells [20]. These mNK effector cells are functionally competent and are 
capable of producing cytokines and causing cytotoxicity. mNK cells emigrate from the 
bone marrow and constitute the main NK cell population in the peripheral lymphoid organs 
e.g. spleen and lymph nodes [21]. Based on the density of CD27 (member of surface TNF 
receptor superfamily, binding CD70) and Mac-1 (CD11b integrin, adheres to extracellular 
matrix), four developmental subsets having different functional capacities, have been 
identified in the periphery [21], also considered as the four terminal maturation stages in 
NK development [22]. Upon activation, however, NK cells may change surface expression 
of markers [20].  
NK cells also express a variety of surface markers, some of which are tightly associated with 
a function. Many of them mark the different developmental stages in NK cell lymphopoiesis. 
DX5 (CD49b, binds extracellular matrix) is a component of certain integrins and helps in cell 
migration not only during development and recirculation, but also in wound healing. CD69 is 
an early activation antigen. NK cells also secrete chemokines (e.g. CXL10, CCL3, etc.) and 
express several cytokine receptors (e.g. IL-2R, IL-12R, IL-15R, IL-18R, IL-21R, CXCR3, 
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CCR1, etc.) involved in their proliferation, activation, expansion, immune regulation and 
migration. Among them, IL-21 plays an important role in NK cell expansion [23-28]. IL-15 is 
specifically required for NK cell lymphopoiesis. IL-15 and interaction with dendritic cells 
(especially in lymph nodes) are important for their development, survival, activation and 
proliferation [29]. Other markers are associated with cytotoxicity e.g. granzymes, granulysin, 
CD107α, Fas ligand, TRAIL, etc. [29, 30]. 
In humans, based on the selective density of surface CD56 (an adhesion molecule) 
expression, two subsets have been identified. CD56dim NK cells constituting about 90%, are 
the major cytotoxic subset whereas CD56bright, making up about 10%, are the major cytokine 
(e.g. IFN-γ) producers [30]. 
1.2.4   Role  in  physiology  and  pathology  
Due to their multifaceted effector functions, NK cells play important roles in physiological 
conditions e.g. pregnancy, as well as in disease situations e.g. viral infections, tumour 
rejection, etc. More aspects of NK cells’ functions are currently being investigated in 
research. A few physiological and pathological states are described below.  
1.2.4.1   Role in pregnancy  
NK cells play an important role under physiological conditions in pregnancy. Under 
hormonal influence during pregnancy, a population of peripheral blood CD56bright CD16- NK 
cells, referred to as uterine NK cells, is recruited to the materno-foetal interface. This is 
interesting as it is a site of semi-allogeneic interaction where NK effector cells should exhibit 
a missing-self response and eradicate foreign tissue. On the contrary, under physiological 
conditions, here they expand and take part in immunomodulation i.e. immunoregulation. 
They promote trophoblast and placental growth via angiogenesis without maternal 
immunosuppression or foetal rejection, and which may be attributed to the release of 
transforming growth factor- β (TGF-β). This is important for implantation and maintenance 
of pregnancy and abnormalities in this process lead to an unfavourable environment for the 
embryo/foetus in the uterus leading to abrogation of pregnancy. This is also another indicator 
of how NK cells adapt their responses depending on the environment and regulate immune 
environment [31-34]. Outcomes of pregnancy and foetal health parameters have been related 
to maternal KIR (Killer immunoglobulin like receptors, NK cell receptors in humans and 
described in detail later) expression. Paternal HLA (Human leukocyte antigen, major 
histocompatibility complex antigens class I (MHC-I)) has also been seen to play a role, in 
that, certain combinations of maternal KIR on uterine NK cells and paternal HLA molecules 
on trophoblasts, may lead to unfavourable outcomes in pregnancy e.g. recurrent spontaneous 
abortions, pre-eclampsia, intrauterine growth restriction, etc. [35].  
1.2.4.2   Role in infections  
NK cells play important roles in fighting infections, especially those caused by intracellular 
pathogens e.g. viruses, bacteria, protozoa (e.g. Leishmania), parasites (e.g. Toxoplasma 
gondii) [36]. Presence of NK cells in organs allows them to fight specific infections e.g. viral 
infections in the liver. Due to the nature of their responses, they might also participate in 
disease pathogenesis in addition to their anti-viral effects [37]. Investigation of NK cell 
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responses in context of many infections has shown that they are among the first responders 
and expand in response to e.g. MCMV (mouse cytomegalovirus), HCMV (human 
cytomegalovirus), Listeria monocytogenes, Herpes, Hepatitis B and C, Hanta virus, 
Chikungunya virus etc. [29, 38-41]. In HIV infection, NK cells help in infection control by 
killing infected cells [36].  
Studies have shown that due to their memory-like and antigen-specific responses to viral 
infections and crosstalk with other immune cells e.g. dendritic cells, etc., their role in viral 
infections is complex and not limited to that of a classical innate immune cell [42]. Although 
NK cells have been considered as innate immune system components and thus unable to 
mount memory-based responses ascribed to the adaptive immune system, studies have shown 
that prior antigen activation plays a role in enhancing NK cell responses. For example, in the 
case of MCMV infection, Ly49H+ NK cells antigen specific for MCMV protein m157, 
respond faster. Once activated, some of these cells remain as long-lived, highly responding 
cells, reminiscent of memory T cells [43]. Other memory-like responses by NK cells can be 
induced by cytokine stimulation without any known antigen dependency [44]. 
1.2.4.3   Role in autoimmunity 
NK cells have been studied in a variety of autoimmune diseases and experimental models. 
The picture is very complex and there is evidence that NK cells can either promote or 
counteract autoimmunity, even within the same disease. This may depend on the phase of 
disease development [45]. NK cells may cause severe tissue damaging inflammations in 
response to viruses [40]. Some examples of autoimmune conditions where NK cells have 
been suggested to play a role in pathogenesis include Juvenile Rheumatoid Arthritis, Type 1 
Diabetes, Autoimmune Thyroid diseases, etc. [46-49].  
1.2.4.4   Role in transplant & tumour immunology 
NK cells mediate bone marrow rejection even in irradiated in mice, and play a role in the 
pathophysiology of graft versus host disease (by preventing it). Recent studies have shown 
that they influence solid organ allografts as well [50]. As mentioned earlier, they play a vital 
role in killing tumours especially those of the haematopoietic and lymphoid system. Primary 
or transplanted tumours in mice grow better in NK cell depleted conditions [51]. The same 
has been observed in solid organ tumour studies, where several strategies are being 
investigated that may increase NK cell potential to kill cancer cells within the tumour 
microenvironment [52]. These roles of NK cells are discussed in more detail later.  
1.3   MAJOR  HISTOCOMPATIBILITY  COMPLEX  CLASS  I  MOLECULES  
Major histocompatibility complex (MHC) molecules are cell surface proteins expressed on 
almost all nucleated cells in the body. There are two types, major histocompatibility complex 
I (MHC-I) and major histocompatibility complex II (MHC-II), both encoded by a 
polymorphic set of genes located on chromosome 17 in the mouse. For MHC-I molecules, 
two subfamilies called classical (MHC-Ia) and non-classical MHC-I (MHC-Ib) molecules 
have been described. They are structurally similar, but differ in many features; for example, 
the former are highly polymorphic whereas the latter are more conserved. Generally, MHC-I 
refers to classical MHC-I unless mentioned otherwise. An MHC-I molecule consists of two 
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polypeptide chains, the α chain having three domains (α1, 2, 3) and a β2-microglobulin chain 
(β2m), which are linked non-covalently. Only the α chain is polymorphic and encoded by an 
MHC-I gene. Its α1 and α2 domains form a cleft capable of binding antigens, usually short 
(8-11 amino acids) peptides. The β2m subunit is non polymorphic, encoded by the β2m gene 
and associates with the α chain to help maintain the proper conformation of the MHC-I 
molecule, necessary for its expression on cell surface. β2m knockout mice (β2m-/-), therefore, 
have greatly reduced MHC-I cell surface expression [53]. Studies in mice and human differ 
as mouse research is done on mostly inbred laboratory strains, allowing a reductionist 
approach in these studies.  
In humans, MHC-I molecules are referred to as HLA (human leukocyte antigens) while 
classical MHC-I molecules in mice are termed H-2. The H-2 complex on chromosome 17 
includes three MHC-I loci: D, K and L, each with multiple alleles. The H-2 haplotypes in 
various laboratory mouse strains have been characterized extensively and used in studying 
immunological processes, especially by mouse models obtained via breeding or transgenic 
technology. Homozygous inbred mice strains have unique H-2 haplotypes termed as e.g. H-
2a, b, d, k, q, s, etc., where each haplotype refers to a particular combination of alleles at the K, D 
and L loci. The H-2 haplotype of the C57BL/6 mice (B6) is H-2b, which contains Kb and Db 
alleles, and a null allele at the L locus. Other examples of H-2 haplotype are H-2d in Balb/c 
and DBA, which contain Kd, Dd and Ld alleles. Figure 2 shows the schematic structure of the 
H-2Dd molecule and an engineered derivative, in which the α3 domain is derived from Ld. 
The latter transgene has been introduced in the DL6 mouse which is the focus of this thesis.  
The MHC-I and MHC-II molecules play a crucial role in antigen presentation. When MHC-I 
molecules are produced inside the endoplasmic reticulum of the cell, they bind peptides 
synthesized within the cell, usually from endogenous proteins, but during infection, they can 
also load microbial (e.g. viral) peptides. These peptides are actively transported into the 
endoplasmic reticulum via transporters associated with antigen presentation or TAP 
molecules. Upon traffic to and expression on the cell surface, the MHC-I molecules present 
these peptides to CD8+ T cells, whose T cell receptors can bind and dock to combine 
elements of the MHC-1 molecule and the peptide [54]. 
Another function of MHC-I molecules is to act as ligands for NK cell receptors such as Ly49 
receptors (Ly49r). The different inhibitory Ly49 receptors bind MHC-I molecules, each with 
a certain allele specificity or at least allele preference, as described later [53]. This specific 
interaction forms the basis of the ‘missing-self’ hypothesis. These receptors will be discussed 
more in detail below, but it is pertinent to already here mention some structural aspects 
regarding their interaction with MHC-I. This binding usually requires a peptide in the antigen 
binding cleft, and although some peptides are more permissive for certain Ly49r, the latter do 
not distinguish peptides with the same fine specificity as T-cells. The Ly49r/MHC-I 
interaction is quite different from the T cell receptor/MHC-I interaction; in most cases the 
NK cell receptor docks to the MHC-I ligand close to the α1 α2 helices, but may also bind 
near the floor of the antigen binding groove close to α3 helix [53, 55, 56].  
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1.4   NATURAL  KILLER  CELL  RECEPTORS    
The NK cells receptors serve various functions including roles in development, maturation, 
education and effector function [57]. Many of these receptors are not limited to NK cells and 
may be expressed on other immune cells e.g. dendritic cells, T cells, etc. [58]. They include a 
variety of adhesion molecules as well as cytokine and chemokine receptors. 
The main receptors involved in NK cell function are the inhibitory and activating receptors 
that take part in cognate interactions with other cells. NK cells possess a host of germ line 
encoded receptors, both inhibitory and activating in nature. These receptors comprise 
proteins from various families and with different specificities. Host MHC-I alleles 
influence the expression and function of some of these receptors, and in many cases, 
influence their cell surface expression levels as well (discussed further in the education 
section 1.6). 
 
Many of the inhibitory receptors interact with MHC-I and similar molecules expressed by 
all healthy nucleated cells, while the activating receptors, in addition to MHC-I, interact 
with a host of endogenous or exogenous proteins related to stress, senescence, non-self, 
pathology, etc. Many ligands have been identified for both types of receptors, although they 
are not well characterized, especially for the activating receptors.  
The NK cell recognition system for target cells depends on interaction between multiple NK 
cell receptors and the corresponding ligands on the target. The receptors for target recognition 
act in concert, adding up to a net signal resulting from the balance of activating and inhibitory 
receptors.  
1.4.1   Inhibitory  receptors  
NK cell inhibitory receptors consist of various families. In mice, the major inhibitory receptor 
family belongs to the type II integral membrane C type lectin protein family. These NK cell 
receptors are known as Ly49 receptors (recently termed as klra family killer cell lectin-like 
Figure 2. Schematic picture of MHC-I molecules encoded by different transgenes used in 
the thesis. 
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receptor, subfamily). They represent a multigenic family located on chromosome 6. In 
humans, they exist only as pseudogenes. Like the MHC-I complex, the Ly49 gene locus is 
diversified in terms of alleles and ligand specificity, showing considerable differences among 
mouse strains, thus uniquely affecting immune responses in them [57]. 
Most of these receptors display some MHC-I allele preference, but the specificity is not 
limited to one MHC-I ligand. Moreover, the binding of one receptor to different MHC-I 
ligands can vary quantitatively e.g. the Ly49A receptor binds strongly to Dd. The Ly49C 
receptor binds strongly to Kb. The Ly49G2 receptor binds to Dd. The Ly49I receptor binds to 
Kb and Db. There are also a number of weak interactions that have been described using 
different binding assays as well as functional assays e.g. Ly49C binds weakly to Db, Ly49A 
to Db, Ly49G2 to Ld, Db, etc. [13, 59-65]. Another type of inhibitory receptors is 
NKG2A/CD94, which are dimers of natural killer type II transmembrane protein family with 
CD94. They recognize class 1b MHC-I in mouse i.e. non-classical Qa-1b, which 
preferentially presents Qa-1 determinant modifier or Qdm, a peptide derived from the leader 
sequence of certain MHC-I alleles i.e. Dd and L [66]. 
The cytoplasmic domains of the inhibitory Ly49r contain immunoreceptor tyrosine based 
inhibitory motifs or ITIMs. Upon recognition of an MHC-I molecule by the receptor, these 
ITIMs are phosphorylated by Src kinases and recruit adaptor molecules like SHP-1 or SHIP-1 
phosphatases, which can act by dephosphorylating substrates like Vav1, thus blocking the 
downstream activating pathways. Via inhibitory signal transduction, the lytic function, 
among others, is downregulated [29, 67]. 
In humans, the inhibitory NK cell receptors include proteins of the killer immunoglobulin-
like receptor family (inhibitory KIRs e.g. KIR2DL, KIR3DL, recognizing specific classical 
1a MHC-I/HLA alleles e.g. HLA-C), natural killer type II transmembrane proteins with an 
extracellular C-type lectin (CD159 family including NKG2A, NKG2C, NKG2E, etc. which 
form dimers with another C- type lectin CD94, recognizing non classical 1b MHC-I 
molecules e.g. HLA-E), etc. [29]. 
Other receptors with inhibitory function present on NK cells include KLRG1 (MAFA, 
binding cadherins) and 2B4 (CD244, binding CD48) in mouse and NKRP1 [68], [69] and 
other SLAM family members [70]. 
1.4.2   Expression  pattern  of  inhibitory  receptors    
 
The Ly49 receptors are expressed in a variegated pattern, such that each receptor can be 
either on or off in a particular NK cell, and this correlates with transcription of the receptor 
gene. This is regulated independently for each of the Ly49 genes and the consequence is 
that each NK cell may express none, 1, 2, 3, 4, 5 or even more different Ly49 inhibitory 
receptors. The expression pattern may be attributed to the presence of bidirectional 
promoters upstream of the Ly49 gene locus or to long-range methylation of the locus. 
Moreover, the probability for "on" differs e.g. in B6 mice 15% of NK cells are Ly49A+, 
while 40% are Ly49C+. The probability to express two Ly49r corresponds to the product of 
the probabilities for expression of each of these receptors (Ly49C and Ly49A: 0.15 x 0.40 
= 0.06), referred to as “the product rule”. Expression is independently regulated for each of 
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the different Ly49 receptors, thus, leading to overlapping expression patterns. Similar rules 
apply to the expression  of KIR in humans [13, 59, 71-74]. 
1.4.3   Activating  receptors    
In mice, NK cell activation receptors include some members of the Ly49 family, e.g. Ly49D 
(recognizing Dd allele of mouse MHC-I), Ly49H (recognizing m157 protein encoded by 
MCMV). NKG2D (CD134) is a member of the natural killer type II transmembrane family; it 
can bind to target cell ligands induced by stress or infections, such as Rae-1β, H-60, MULT1, 
etc. [75]. Other examples of activating receptors are NKR-P1C (NK1.1 or CD161.c, 
belonging to a family of receptors encoded in the mouse NK complex, NKC), NKp46, 
NKp30 and CD16 (low affinity Fc-γIII receptor). The latter allows NK cells to mediate 
antibody dependent cell mediated cytotoxicity (ADCC), a reaction that may be an important 
effector mechanism for many antibodies used as drugs to treat tumour patients. The ligands of 
the other mentioned receptors are less clear, although some candidates have been suggested 
(e.g. influenza virus hemagglutinin in the case of NKp46). It should be noted that normal, 
healthy cells are killed by NK cells if they lack MHC-I molecules, which means that certain 
ligands for activating NK cell receptors must be expressed constitutively. It is not clear 
whether such ligands represent low grade expression of the known ligands for activating 
receptors, or an additional set, of so far unknown group of molecules [29]. 
Many activating receptor families have short cytoplasmic tails, and signal via association 
with adaptor molecules like CD3ζ, FcεRIγ, DAP12, etc., which contain immunoreceptor 
tyrosine based activating motifs or ITAMs. The association with the adaptor molecule occurs 
via a charged residue in the cytoplasmic tail in the case of activating Ly49 receptors, 
interacting with DAP12. The adaptor molecules, in turn, recruit kinases like ZAP70 or syk, or 
other adaptor molecules like DAP10. Thus, the phospho-inositol tri phosphate PI3 pathway of 
cell activation is initiated [29, 30, 67]. 
The various co-activating receptors include adhesion molecules like CD2, CD62L, LFA-1, 
(CD11a, binding ICAMs), etc., and DNAM-1 (CD226) which may be both an activating 
receptor and an adhesion molecule. It binds to CD155 and CD112, and seems to be crucial 
for certain NK-tumour cell interactions, e.g. in melanoma [76].  
In humans, NK cell activating receptors include some proteins of the killer immunoglobulin-
like receptor family (activating KIRs e.g. KIR2DL, KIR3DL, recognizing specific classical 
1a MHC-I/HLA alleles e.g. HLA-C), the NKR-P1A family, natural cytotoxicity receptors 
(NCRs e.g. NKp30, NKp44, etc.), CD16 (Fcγ receptors for the Fc end of IgG antibodies), 
natural killer type II transmembrane proteins (NKG2D or CD314 recognizing stress/altered 
molecules like MICA/B, Hsp90, Rae-1g, MULT1, H-60, ULBP, etc.), to name a few. For 
human NK cells, activation requires the involvment of at least two different activating 
receptors (exception is CD16) [77]. 
1.5   MISSING  SELF  AND  OTHER  RECOGNITION  STRATEGIES  
 
MHC-I alleles specifically interact with Ly49 inhibitory receptors on NK cells. This forms 
the basis of the missing self hypothesis [78]. During effector phase, NK cells interact with 
cells via both activating and inhibitory receptors. The final outcome of the interaction 
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depends on the balance between these signals. When interacting with a normal cell which 
has self MHC-I molecules and none or few activating ligands, the balance is tipped to the 
inhibitory side. On the contrary, when interacting with an altered/foreign cell having 
decreased or no self MHC-I molecules, the balance favours NK cell activation as explained 
by the ‘missing self hypothesis’. The balance can also be altered by expression of proteins 
induced during stress, infections (especially viral), tumour transformation, senescence, etc. 
which bind to activating NK cell receptors [79]. This is referred to as ‘induced-self 
recognition’. Current data suggests that some activating ligands seem to be constitutively 
expressed by normal cells. When an NK cell interacts with a normal cell which has self 
MHC-I molecules and none or few known activating ligands, the balance is tipped to the 
inhibitory side. An inhibitory signal would interrupt the activation signal via 
dephosphorylation of molecules critical for the activation pathway, and inhibits 
cytotoxicity. A change in the inhibitory signal (i.e. reduced MHC-I expression) may be 
sufficient to trigger effector function as one example of extreme situations. Another 
extreme is a target with normal MHC-I expression, but dramatically increased expression of 
activating cell surface ligands induced by stress; under these conditions, the balance is 
tipped to the activating side. One may imagine that the NK cell’s decision may often be 
based on a combination of these changes at the target cell level, e.g. moderately increased 
expression of activating ligands, combined with moderately reduced expression of 
inhibitory ligands. Regardless of the details behind this altered balance leading to effector 
function, the latter may include cytotoxicity as well as cytokine secretion. During the 
maturation phase, the interaction between NK cell receptors, most importantly the 
inhibitory receptors, and MHC-I molecules set the activation thresholds and functional 
capacity of the NK cells, as discussed further below. 
 
While infected and tumour transformed cells both may often increase activating ligands and 
reduce expression of MHC-I, there are certain situations, where a cell without any 
alterations in the activating ligands can be killed, simply because it lacks the critical 
inhibitory self MHC-I ligand e.g. allogeneic cells. When the absence or reduced expression 
of MHC-I play a decisive role, this is referred to as “missing self” recognition [80]. 
Missing self recognition is sensitive and enables NK cells to detect completely missing 
MHC-I molecules i.e. “general” missing self, e.g. in case of β2m-/- cells, and partially missing 
MHC-I alleles i.e. “allele-specific” missing self, e.g. in case of allogeneic cells [81]. It 
explains both the recognition and killing of tumour cells as well as hybrid resistance, an 
occurrence where the F1 hybrid i.e. the offspring from a cross between two inbred strains, 
resists parental grafts, and which classical transplant immunology had failed to explain [13], 
as discussed below. 
1.6   NATURAL  KILLER  CELL  EDUCATION  
 
Classical laws of transplantation are based on the notion that an F1 hybrid contains all the 
histocompatibility antigens present in the parental mice. The latter would reject grafts from 
the F1 but not vice versa. These laws were based on and predicted T cell responses [82, 83].  
However, T cell independent rejection of parental bone marrow grafts was seen in F1 
hybrids in case of mismatched MHC-I molecules, and NK cells were eventually shown to 
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be involved in this. Several models were presented to explain this peculiar type of rejection, 
e.g. recessive Hh antigens [84-86]. Later, studies in transgenic D8 mice having a Dd 
transgene on a B6 (Kb+Db) background, showed that non-transgenic B6 (Kb+Db) bone 
marrow or lymphoma [87] was rejected in such mice contrary to classical transplantation 
laws. This was a significant observation as it demonstrated that the rejection was actually 
due to influence of host MHC-I genes [78, 88].  
 
These studies suggested that MHC-I molecules affected the NK cell specificity 
development. This became clear when the gene targeting technology could provide MHC-I 
deficient mice. Since self MHC-I molecules are important in protecting the target from NK 
cells, it could be assumed that in an MHC-I deficient mouse, all cells would be more prone 
to lysis by their own NK cells. However, in β2m deficient mice, this was not the case. In 
such a setting, the animal’s own NK cells did not kill any MHC-I deficient cells in vivo or 
in vitro [89, 90]. This led to the hypothesis that the presence (or absence) of self MHC-I in 
the host specifically determines the outcome of individual effector NK-target cell 
interactions. This effect has been termed as education [91]. 
 
For most immunologists, the term education equals the term deletion i.e. deletion of clones 
in a selection process. However, other possibilities could not be excluded.  
Previous observations in MHC-I mosaic mice (which have a mixture of cells with respect to 
MHC-I in that some cells express Dd molecule and some do not) showed that NK cells, 
which maintain tolerance to cells with a certain MHC-I phenotype in vivo, lose that 
tolerance upon a change in environment and can lyse those cells. This change in NK cell 
specificity showed their adaptability to changed MHC-I expression in the environment [92]. 
Thus, it was concluded that although NK cells become tolerant to all MHC phenotypes 
present in the host, tolerance to one of them can be broken when cells with this phenotype 
are removed from the environment. This suggested that NK cell tolerance is reversible and 
may be due to mechanisms leading to a temporary anergy-like state in the cells, and not 
from clonal deletion that would have removed the cells altogether. 
 
This was formally proven in 2005, independently by the groups of Yokoyama and Raulet. It 
was known that inhibitory receptor expression is variegated. Some NK cells have self 
specific inhibitory receptors in the host, while some do not. The two groups showed that if 
the NK cells do not express any self-MHC-I specific inhibitory receptors, they do not 
become responsive; their activation threshold is maintained high and they become 
“hyporesponsive”, without having to be inhibited by recognition of MHC-I ligands. But if 
they do express self-MHC-I specific inhibitory receptors, they become responsive 
depending on the cognate self-MHC-I [93]. The hyporesponsive NK cells maintain self 
tolerance, which is MHC-I independent. They do not respond well in assays based on 
activation of NK cell receptors or towards MHC-I deficient healthy cells [93, 94]. Thus, 
NK cells that do not meet a cognate MHC-I ligand are not deleted but kept in a 
hyporesponsive or unlicensed state. This was also observed in human NK cells  [95]. 
Thus, during the maturation phase, the interaction between NK cell receptors, most 
importantly the inhibitory receptors, and MHC-I molecules set the activation thresholds and 
functional capacity at the single NK cell level.  
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Phenotypically, no marker for education has been identified as yet, but functionally, it is 
measurable in a number of ways, at several levels [67, 96]. In mice, at the NK system level, 
educated NK cells can mount a strong rejection response to an in vivo challenge with MHC-
I- cells (measurable by an in vivo assay for NK cell mediated rejection which is described 
later). This can also be tested using in vitro killing assays. At the cellular level, the 
functional capacity of an NK cell can be analysed using single cell responsiveness assays. 
Educated NK cells degranulate and produce more cytokines e.g. IFN-γ, as compared to 
uneducated cells when exposed to antibodies against activating receptors [67, 96].  
In addition, the host MHC influences the frequency distribution of subsets with different 
patterns of Ly49r expression. This influence is exerted at the system level.  
In MHC-I deficient mice, no NK cells have seen MHC-I molecules and many of them 
express multiple inhibitory receptors, whereas in mice with MHC-I expression, due to 
interaction with specific MHC-I alleles, the NK cell receptor repertoire is ‘skewed’ towards 
more single receptor positive NK cells, particularly those specific for self MHC-I [97, 98].  
 
Another observation is that cell surface expression of an inhibitory receptor on NK cells is 
reduced when its ligands are expressed in the host [99, 100]. This can be caused by cis and 
trans interactions with MHC-I, but cannot be used as a marker of responsiveness [29, 101, 
102].  
1.6.1   Models  for  education  
Based on the influence of MHC-I on NK cell function, three models of NK cell education 
have been proposed: 
1)   The Licensing model suggests that NK cells are inactive by default and are 
allowed to mature to full functional potential depending on interactions with self 
MHC-I. Evidence shows that signalling by ITIM containing receptors is 
required for licensing to take place. Unlicensed NK cells remain self tolerant, 
even if they lack inhibitory MHC-I receptor [68, 93].  
 
2)   The Disarming model states that mature NK cells are active by default, but if 
they fail to interact with self MHC-I due to lack of specific receptors or ligands, 
they become selectively disarmed. This NK cell anergy would be a mechanism 
to maintain self-tolerance [69, 94]. 
 
3)   The Rheostat model hypothesizes that NK cells can be continuously and 
reversibly regulated so that they become more or less responsive, depending 
upon the strength (and frequency) of encounters with cognate MHC-I molecules 
[96]. It reconciles both the licensing and disarming models, and is described in 
more detail below. 
1.6.2   The  rheostat  model  
NK cells sense inhibitory signals through their Ly49/NKG2 receptors, which have different 
allelic specificities and affinities for MHC-I. Thus, MHC-I alleles differ in their efficiency in 
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educating NK cells and the number and type of host MHC-I alleles quantitatively influence 
NK cells expressing individual Ly49 receptors [59, 103, 104]. The “sum” of inhibitory 
signals received by an individual NK cell during education, tunes the downstream activation 
pathways quantitatively, synonymous to a “rheostat” controlling an electrical circuit [96] 
(Figure 3). Tuning up results in low activation threshold and high responsiveness, thus 
normal cells would only be protected by adequate MHC-I expression. On the other hand, 
tuning down results in an increased activation threshold towards normal cells. 
 
 
 
This process determines the frequency of responsive NK cells at the population level and also 
control the strength with which, each responsive NK cell exerts its effector functions. Thus, 
for quantitative effector responses like degranulation and cytokine production, the NK cell 
increases its responsiveness, resulting in more IFN-γ production per cell [96]. These two 
effects together lead to a more efficient in vivo missing self response at the organism level. 
This can be interpreted as the ‘educating impact’ of a given combination of MHC-I [59, 96].  
There are several lines of data suggesting that education is quantitative and reversible rather 
than a digital on/off feature. Reversible tuning is consistent with observations in MHC-I 
mosaic mice as described above, as well as with other in vitro and in vivo studies [105] [106]. 
The ‘Licensing’ and ‘Disarming’ models can be reconciled with each other in the rheostat 
model albeit with modifications, where the rheostat model reflects bidirectional tuning, up or 
down, of NK responsiveness as opposed to switching the cell on or off. Even after the 
maturation in bone marrow, NK cells would continuously undergo small licensing or 
disarming steps. Thus, mature NK cells constantly adjust to the MHC-I environment by 
continuously tuning their responsiveness upwards or downwards, depending on the net 
inhibitory input of the environment, to maintain optimal responsiveness with respect to 
‘missing self’ recognition while preserving self tolerance [67, 96].  
Figure 3. The rheostat model. NK cell responsiveness is tuned at a single cell level. 
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Licensed NK cells or NK with a majority of Ly49 (inhibitory) receptors specific for self 
MHC-1, respond to minor changes in MHC-1 repertoire/expression e.g. in 
tumours/transplants. Unlicensed NK cells are not non-functional cells. Although they are 
not responsive to normal cells in the host environment, they have been shown to respond 
vigorously to infections. They are dormant but can be awoken by increased activating 
signals e.g. in case of infections like MCMV or Listeria [94, 107]. 
The rheostat model states that this is a reversible and quantitative phenomenon, depending on 
the amount of signals a cell receives. Assuming NK cells incorporate this input over several 
cell encounters, it may also depend on the ratio between cells with and without a critical 
MHC-I ligand. This can occur under conditions of chimaerism after haematopoietic 
transplantation. One major aim of this thesis was to address whether education for NK cell 
responsiveness and missing self rejection in vivo is influenced quantitatively by the frequency 
of cells with a given MHC-I ligand. 
1.7   NK  CELLS  IN  NATURAL  RESISTANCE  AGAINST  CANCER  
Evidence that NK cells can contribute to natural resistance against transplantable tumours 
was presented already soon after the discovery of NK cells in the 1970s. Kiessling et al. 
showed that in different F1 hybrid strains of A/Sn mice, the natural resistance against the semi 
syngeneic YAC lymphoma cells correlated with the NK cell activity against the same tumour 
cells in vitro [108]. They also demonstrated such resistance in athymic nude mice and mice 
treated with thymectomy, irradiation and reconstitution of bone marrow cells, arguing against 
a role for T cells [109]. These correlative studies were eventually followed by more direct 
studies based on NK cell depletion with antibodies such as anti-asialo-GM1 and anti-NK1.1, 
both of which could abrogate natural resistance against transplantable tumours [110-113]. 
Experiments along this line also demonstrated that NK cells were particularly efficient in 
protection against haematogenous metastasis, e.g. in studies of intravenously inoculated B16 
melanoma cells [114]. 
The early studies where based on long term evaluation of growth (or metastasis) of tumours. 
These experiments can cause suffering of animals, even if ethical guidelines on maximal 
tumour size is followed. Furthermore, they are time consuming and the outcome can be 
influenced by a variety of factors. Several different assays for direct monitoring of NK cell 
mediated killing in vivo of intravenously inoculated (radio labelled or fluorochrome labelled) 
tumour cells have therefore been developed, including some new protocols presented in the 
results part in the present thesis [115-117]. Such methods have been particularly useful to test 
the influence of MHC-I genes in missing self based recognition and resistance against 
tumours.  
More recently, it has been addressed whether NK cells contribute to natural resistance against 
tumours in their host of origin (autochtonous host). These studies have used chemical 
carcinogenesis or transgenic models based on oncogene driven tumour development. [51, 
118], and show an important role of NK cells in host protection. NK cells in 
immunosurveillance against tumours in humans is of course much more difficult to study, 
although attempts have been made in correlative studies. A role of NK cells was suggested 
from a study in which NK cell levels were studied longitudinally with a 11 year interval using 
a functional cytotoxicity readout, which showed that a high level of cytotoxic activity among 
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peripheral blood lymphocytes was associated with a lower risk of cancer [119]. Similarly, 
high numbers of tumour infiltrating NK cells correlate to higher survival in several solid 
tumours [120, 121]. 
1.8   NK  CELLS  IN  IMMUNOTHERAPY  AGAINST  CANCER  
Regardless of the role of NK cells in natural resistance against cancer, they are interesting in 
the perspective of immunotherapy against cancer. This has been exploited in experimental 
studies in mice and NK cells are now also being studied extensively for the purpose of 
clinical use. Immunotherapy is a rather new arm of cancer treatment along with conventional 
methods like surgery, chemotherapy, radiation, etc. NK cell activity can be harnessed or 
modified in various ways to induce or improve their therapeutic efficacy in cancers including, 
including cytokine activation, transfer of cells, antibody mediated effects, genetic engineering 
or combination of these different methods. 
1.8.1   Cytokine  activation  of  NK  cells    
NK cells can be activated by several cytokines, such as IFN-β, IL-2 and IL-15. The latter can 
also be used to expand and maintain NK populations, in vivo and in vitro. The first direct 
studies of NK cells in immunotherapy were done by S. Rosenberg and colleagues using IL-2 
activated mouse spleen cells or human PBMC [122, 123]. These cells were referred to as 
lymphokine activated (LAK) cells and proposed to represent a novel immune cell population, 
but later studies showed that the majority of the effector cells in these cultures were activated 
NK cells [124]. After activation and expansion in vitro, the cells were transferred back to the 
NK cell donors (tumour bearing mice or cancer patients), with or without concurrent 
treatment with IL-2 injections. This approach resulted in some tumour regression effects also 
in clinical situations, however, there were severe side effects (e.g. pulmonary oedema). IL-2 
treatment alone is still being used in treatment of certain cancers [125, 126]. IL-2 can also be 
combined with drugs, for example in case of AML (acute myeloid leukaemia), the combined 
use of low dose IL-2 with HDC (histamine dihydrochloride), has been shown to reduce the 
risk of relapse significantly, post remission [127, 128]. 
These pioneering studies have then been further developed, and today a number of protocols 
are being used to generate large numbers of NK cells ex vivo [129]. GMP (good 
manufacturing practice regulations) compliant protocols for clinical grade NK cells are being 
developed and tested for efficacy and safety, using bioreactors with cytokines and feeder 
cells. CIK (cytokine induced killer cells) generated by use of IL-15 and IL-21 for NK cell 
differentiation and maturation do not need priming in vivo, by exogenous IL-2 administration 
[130, 131]. 
A recent approach in this field is to exploit the features of so called memory NK cells, e.g. 
cells which after activation or prolonged stimulation (with cytokines or CMV), show 
increased efficacy and survival. Such memory-like NK cells have increased functional 
capacity for long-term (weeks) on re-encountering cytokines or tumours (leukaemia targets), 
be it licensed or unlicensed NK cells [132]. 
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1.8.2   Harnessing  allo-­  and  missing  self  recognition  in  haematopoietic  
transplantation  and  adoptive  transfer  of  NK  cells  
An effective post-remission therapy for acute leukaemia patients with high risk of relapse, is 
allogeneic haematopoietic stem cell transplantation (HSCT)/HLA-haploidentical HSCT. 
Extensive matching of HLA is required to prevent rejection and graft versus host disease i.e. 
GVHD. In cases when matched donors were not available, attempts were made to use partly 
matched donors, for example haploidentical ones, where only one HLA haplotype was 
matched. This is often the case if the donor is a parent of the recipient. Earlier, it was 
observed that haploidentical (HLA haplotype mismatched) transplantation elicited allo-
responses, both rejection and GVHD. The GvL effect of T cells was overridden by their 
GVHD effect. To counteract this, high dose, extensively T cell-depleted peripheral blood 
haematopoietic progenitors were transplanted, with no post transplant immunosuppression. 
This brought focus on the alloreactive role of NK cells, in eradicating AML [133]. 
The application of NK cell mediated missing self reactivity in immunotherapy was pioneered 
by Velardi et al. in studies of haplo-identical HSCT i.e. transplantation between two persons 
sharing one HLA haplotype (often parent to child transplants). Ruggeri et al. observed that in 
such HLA mismatched HSCT cases, where there was a predicted donor versus recipient NK 
allorecognition (i.e. allele specific missing self recognition), donor NK clones obtained from 
transplanted recipients killed recipient target cells in vitro, but did not cause GVHD (graft 
versus host disease). These KIR ligand mismatched donor stem cells also showed better 
engraftment [134]. In a follow up study, it was shown that NK cell alloreactivity in 
haploidentical HSCT could not only protect from graft rejection and GVHD, it could also 
prevent leukemia relapse in AML patients. Furthermore, in a mouse model, infusion of KIR 
ligand mismatched NK cells before transplant, not only correlated with reduced leukaemia 
relapse and fewer cases of graft rejection and GVHD, but also lowered the risks associated 
with conventional conditioning regimens followed in transplant protocols [135]. The results 
of the HSCT were confirmed by several studies [136-139]. However, other studies with 
mainly unrelated partly matched BM donors did not reveal an advantage of donors with 
potential for NK cell missing self reactivity in the graft vs. host direction [140-143]. The 
reason for these discrepant results (reviewed by Witt and Christiansen [144]) may be due to 
differences in protocols. It appears that the beneficial effect of NK cell missing self reactivity 
requires exhaustive T cell depletion and a high number of haematopoietic stem cells in the 
graft. The KIR genes play an important role in this, suggesting that KIR allele typing may be 
important in selecting a donor [145]. It has been seen that the responding patients have more 
alloreactive donor NK clones [146]. 
Alloreactive NK cells (i.e. those that express KIRs, which do not recognize HLA class I 
molecules on recipient cells) from haploidentical donor HSCT, prevent graft rejection in the 
absence of GVHD, and reduce relapse by killing patient dendritic cells, T cells and leukaemia 
blasts/residual leukaemia cells (especially in AML patients) [147]. A correlation has been 
seen between the size of this allreactive NK cell population and clinical outcome [148]. Thus, 
allogeneic NK cells have anti-tumour potential like T cells, do not cause GVHD and do not 
require HLA matching of donor and recipient [145], [129]. To further improve this, new 
approaches are being studied e.g. to expand them in vitro [149] as well as standardizing the 
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protocols for clinical generation of alloreactive NK cells [150] for improved clinical outcome 
[151, 152].  
Early results from NK cell infusion based clinical trials have shown feasibility and safety 
without the occurrence of cytotoxicity or GVHD [131, 153, 154], with remission and disease 
free survival seen in some patients with haematological malignancies. This safety was also 
seen in case of haploidentical NK cell infusion, after relapse in AML or MDS 
(myelodysplastic syndrome) patients post allogeneic HCT (haematopoietic cell 
transplantation) [145]. Similar results have been obtained from studies for adoptive NK cell 
based therapy from haploidentical donors [155]. In AML patients after HLA mismatched 
allogeneic HSCT, post transplant adoptive transfer of donor NK cells, especially activated 
NK cells, showed better results than un manipulated donor lymphocyte infusions (DLIs) 
[156]. The efficacy of this method of treatment is further enhanced by the milder protocols 
involved, such as a lack of need for irradiation. In elderly AML patients, who are not eligible 
for HSCT, adoptively transferred haploidentical NK cells, especially in high numbers, 
(purified alloreactive NK cell infusions) post complete remission, has shown to be effective 
and safe [146, 157]. In paediatric patients of AML, there was a higher relapse and lower 
survival compared to other paediatric cancers. NK cell adoptive transfer reduces the need for 
chemotherapy and eradicates AML blasts [158]. The objective is to maximize NK cell 
alloreactivity for achieving effective GvL and no GVHD [145, 159, 160]. 
Studies have investigated the effects of NK cells in inducing graft versus leukaemia (GvL) 
and GVHD not only in case of AML, but also other haematological diseases including 
sarcomas, carcinomas, brain tumours, etc. [131]. The results from solid tumour patients, 
however, have not been so positive [155]. 
1.8.2.1   Cancer treatment based on antibodies 
1.8.2.1.1. Possible contribution of NK cells via ADCC in different situations 
As noted above, NK cells can use the CD16 receptor to mediate ADCC against antibody 
coated target cells. There are a number of antibody based drugs used in oncology today, most 
of which have target molecules expressed on tumour cells. Surprisingly little is known about 
the exact mechanisms behind therapeutic efficiency, but this is not easy to study in the 
human. Using mice with different gene targeting induced deficiencies in Fc receptor (FcR) 
expression, it has been clearly demonstrated that ADCC play a major role in certain anti-
tumour effects induced by administration of antibodies [161]. It has been proposed that some 
of the therapeutic effects seen in clinical treatment may also depend on ADCC and that NK 
cells therefore play a role. One example is the drug Herceptin (antibodies against the HER-
2/Neu growth factor receptor [162] used to treat some forms of breast cancer. There are 
studies suggesting ADCC as mechanism here, because patients with a polymorphism for the 
CD16 receptor respond better and thus, these polymorphisms may carry a predictive value for 
progress [163, 164]. It is, of course important to understand if NK cell mediated ADCC is 
involved in certain therapies, because the efficacy of the treatment can then be improved by 
modifying the antibody (e.g. higher affinity to Fc-receptor) or by combining it with other NK 
cell activating modalities, be it cytokines or other antibodies. 
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A more recent development in this area is the use of genetically engineered antibodies, 
generating bi- or tri-specific antibody complexes which target several different molecules on 
the tumour cells and the effector cells [165]. In this approach, the antibody complex is usually 
designed to target one or more of the activating receptors on NK cells. 
1.8.2.1.2 Blockade of inhibitory receptors 
1.8.2.1.2.1 KIR/Ly49r blockade  
Another way to harness “missing self recognition” for immunotherapy is to block inhibitory 
receptors. According to the hypothesis, this should induce NK cells to kill tumour cells but 
possibly also normal cells expressing MHC-I molecules, since one normal guard to ensure 
self tolerance is blocked. The rationale to explore this approach for immunotherapy was that 
the threshold for NK cell reactivity to tumour cells might be easier to overcome, due to 
different properties of the tumour cells (e.g. the expression pattern of activating ligands). 
There was thus a possibility for “therapeutic interval” where inhibitory receptor blockade 
would result in anti-tumour activity, without attack of normal cells.  
Koh et al. were the first to demonstrate that inhibitory Ly49 receptor blockade in mice could 
result in augmented tumour resistance [166]. These authors demonstrated that anti-tumour 
activity of NK cells increase in vivo as well as in vitro, after inhibitory KIR receptor 
blockade. This has been confirmed by follow up studies showing that short term effect of this 
approach can be utilized to eliminate tumour cells before autologous transplant, without long 
term effects [167-169]. An anti-KIR human antibody was generated and in humanized mice, 
it mediated enhance NK cell lytic activity against AML tumour cells as well as stable 
blockade and long term survival [170]. Using an anti-KIR antibody in combination with anti-
CD20 antibody (rituximab), increased the anti-lymphoma killing capacity of the NK cells in 
vivo and in vitro [171]. 
Vahlne et al. in our laboratory were the first to explore whether the treatment really induced 
NK cell mediated killing of tumour cells in vivo, and also whether NK cell attack on normal 
cells occurs in parallel [168]. This study used an in vivo assay to measure NK cell killing of 
fluorochrome labelled tumour cells and normal cells, in B6 mice that had been treated with 
F(ab’)2 fragments of an antibody against Ly49C and Ly49I receptors (5E6), i.e. a similar 
protocol to the one originally used by Koh et al. [166]. The inhibitory receptor blockade 
could indeed induce augmented in vivo killing of MHC-I expressing RMA lymphoma cells, 
while there were no signs of attack on MHC-I expressing B6 spleen cells, even after 
prolonged treatment (up to 13 weeks). Nor was there any killing of normal cells observed if 
mice were treated with the NK cell activating cytokine IL-2 in parallel with the inhibitory 
receptor blockade, even if this treatment further augmented the induction of lymphoma cell 
killing. Extensive investigations on haematological parameters and histopathology of a 
variety of organs revealed no signs of autoreactive attacks in mice treated up to 13 weeks. 
This study thus supported that there is a therapeutic interval for inhibitory NK receptor 
blockade. However, the rather modest augmentation of tumour cell killing, and the strikingly 
robust tolerance to normal cells observed in treated mice raised the question whether the 
perturbed sensing of MHC-I by inhibitory receptors might have more complex consequences 
than blockade of the inhibitory self recognition during the effector target interaction. This is 
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further explored in the results and discussion, as it is one of the questions posed in the studies 
of this thesis.  
A full understanding of all consequences of perturbed sensing of NK cell inhibitory receptor 
blockade is essential in order to understand and develop efforts to apply this concept 
clinically. Several clinical trials have been completed or initiated, based on these initial 
observations. A number of studies and some clinical trials are under way to study the efficacy 
of different KIR blocking antibodies alone or in combination, and their outcomes e.g. in 
multiple myeloma, lung cancer, etc. [172-174]. 
1.8.2.1.2.2. Blockade of inhibitory receptors other than KIR/Ly49 Receptors 
It has been observed that a pan-HLA blocking antibody makes AML and ALL lymphoblasts 
susceptible to killing by KIR mismatched NK cells. Additionally, blocking inhibitory 
receptors increases killing as does double blocking of other inhibitory receptors like LIR-1 
and NKG2A. Combined with KIR blockade, blocking of LIR-1 and NKG2A shows potential 
for NK cell therapy in acute leukaemias (like 5E6 i.e. anti-Ly49C/I F(ab’)2) [175]. 
T cell intervention has been the more common form of immunotherapy e.g. T cell checkpoint 
blockade [176-179]. Tumour or associated cells may suppress immune cells in vivo, via 
inhibitory soluble factors, cytokines or by engaging immune check-point molecules (e.g. 
PD1/PDL-1) [148, 180, 181].  
The benchmark of immunotherapy i.e. CD8 T cell checkpoint inhibitors (CTLA-4, PD-1/PD-
L1) cause expansion and activation of tumour-specific T cells to circumvent tumour induced 
immunosuppression and eliminate transformed cells. This leads to dramatic anti-tumour 
responses in some patients with advanced melanoma or lung cancer. Several other forms of 
cancer are now evaluated with these as well as novel agents for checkpoint blockades. This is 
a very promising area, in particular when the new drugs are combined with each other or with 
established therapies. Possible limitations are autoimmune side effects e.g. colitis. More 
research is required to predict anti-tumour responses and prevent side effects [157, 177, 178].  
1.8.2.2   Genetically engineered NK cells (including CAR) 
Modified NK cells can be genetically engineered transiently via mRNA electroporation, or 
permanently by viral transduction. The gene modifications include introduction of activating 
receptors, silencing of inhibitory receptors or redirecting NK cells to tumour killing via CARs 
(chimaeric specific antigen receptors) to enhance their specific cytotoxicity or to improve 
survival by autocrine cytokine stimulation in vivo. The CAR therapy has originally been 
developed for T cells, and appears very efficient in treatment of B cell lymphomas [182]. In 
theory, NK cells should be possible to be used also; they may even represent some 
advantages, and it has been suggested that NK cells are “..the better CAR-drivers” [183]. 
Cytokine production by NK cells can be induced to promote in vivo expansion [129], these 
genetic modifications enhance NK cell function and target specificity [131, 184, 185]. 
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1.9   BONE  MARROW  CHIMAERISM  IN  THE  CLINIC  AND  IN  EXPERIMENTAL  
MODELS    
1.9.1   Clinical  studies  
Chimaerism refers to a situation where an organism  is composed of two or more different 
populations of genetically distinct cells, derived from different zygotes. Chimaerism can be 
inborn or induced, e.g. by transfusion or an allogeneic haematopoietic stem cell transplant. 
The latter procedure is a life saving procedure that is used for example in haematologic 
malignancies, congenital immune deficiencies and metabolic disorders. It is estimated that 
more than 50,000 transplantations are performed every year worldwide. For successful 
engraftment, harsh preconditioning usually involving side effects, is used. In case of radiation 
susceptible malignancies (e.g. haematological like CML (chronic myeloid leukaemia) and 
AML), whole body lethal irradiation and/or cytostatic drugs are used. Despite these measures, 
diseased tissue may remain and lead to relapse of malignancy (MRD; minimal residual 
disease). Another complication is GVHD, which is frequently seen in mismatched bone 
marrow transplantation [186]. A number of studies have described chimaerism associated 
with clinical transplantation and also how this condition affects tolerance in the T cell 
compartment. [187, 188]. 
Stable donor chimaerism (sometimes defined as >95% of donor derived haematopoietic 
cells), is aimed for in allogeneic bone marrow transplantation. High levels of residual 
recipient T cells may be related to graft rejection [189] and malignancy relapse. Conversely, 
correlations between high donor T cell chimaerism and GVHD have been reported [190]. 
However rarely, stable mixed donor/host haematopoietic chimaerism (hereafter referred to as 
mixed chimaerism) is established (5-95% host derived haematopoietic cells) [191, 192]. In 
the case of stable mixed chimaerism in patients with non-malignant diseases, mixed 
chimaerism did not correlate with any adverse effects, suggesting that tolerance had been 
established [191, 192]. In addition, mixed donor chimaerism has been reported in patients 
receiving double umbilical cord blood transplantation [193], as well as in patients who have 
undergone repeated bone marrow transplantations [194].   
In organ transplantation, for example kidney transplants, methods to induce transplantation 
tolerance have been widely studied. If successful, the need for lifelong immunosuppression or 
harsh conditioning can be bypassed. One approach is to achieve mixed haematopoietic 
chimaerism i.e. engraftment of donor haematopoietic stem cells (especially HLA-
mismatched) into minimally preconditioned recipients, leading to transplantation tolerance 
[187, 195, 196]. Studies of tolerance induction in mixed chimaeric mice (and other animals) 
have been done, along with early clinical trials [187]. 
Results from recent clinical trials show promise where BMT (bone marrow transplantation) 
from living donors was given to kidney transplant recipients leading to mixed chimaerism 
and allograft tolerance in MHC matched and mismatched transplants. This reduced the need 
for immunosuppression [187, 195]. Mixed chimaerism has been reported to induce donor 
specific tolerance, where in the absence of immunosuppression and extensive conditioning, 
there is less risk of rejection. Even if chimaerism is transient (primate and human studies), the 
benefits achieved are similar to those from durable chimaerism (murine studies) [196]. 
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It is thus clear that mixed chimaerism can affect T cell tolerance. In order to use this 
optimally, the complex relationship between chimaerism and tolerance i.e. the central and 
peripheral mechanisms, both deletional and regulatory, which lead to tolerization in mixed 
chimaeras, need to be explored and understood in order to improve efficacy, introduce 
modifications and remove limitations faced in clinical transplant immunology. Not only that, 
it gives us a chance for better understanding of tolerance through mixed chimaerism [196]. 
Long term NK cell tolerance after allogeneic HSCT that was either KIR ligand matched or 
mismatched, was assessed in a study. It was found that the donor ligands determine NK cell 
education after transplantation, leading to an education pattern similar to that of the donor, 
which was stable for over 3 years post transplant ([197]. 
Mixed haematopoietic chimaerism can occur in humans without intentional transplantation or 
transfer of cells as a part of a medical procedure, but rather initiated during pregnancy [198]. 
Natural chimaerism is observed in several species of protists, plants, invertebrates, vertebrates 
and mammals. It may occur even after “natural transplantation” of somatic cells between 
adult individuals [199]. 
Natural haematopoietic mosaicism has also been described in humans, although to my 
knowledge, not with respect to MHC expression. Genetic mosaicism refers to the presence of 
two (or more) populations of cells with different genotypes, although they originated from a 
single fertilized egg. One form observed in humans is cytogenetic mosaicism, where a 
proportion of all haematopoietic cells carry certain large chromosomal anomalies that have 
arisen due to somatic mutations or genomic instability. The frequency in the population of 
such clonal mosaicism was in one study reported to be low (<0.5%) up until 50 years of age, 
but 2–3% in the elderly [200].  
In the strict definition, genetic mosaicism should be based on cells with different genetic or 
chromosomal constitution, but the term is frequently used in the context of X-chromosome 
inactivation in females, who in each tissue carry a mix of cells where either the paternal or 
maternal X-chromosome is inactivated. This can be regarded as epigenetic mosaicism leading 
to genetically identical cells presenting a mosaic expression pattern. The main mouse model 
used in this thesis, DL6 mice, may represent an (non X-linked) epigenetic mosaic with 
respect to expression of an MHC class I transgene.  
1.9.2   Experimental  studies  
As noted above, allogeneic bone marrow transplant is a life saving procedure in the clinic. 
Furthermore, irradiation bone marrow chimaeras have been, and still is an important 
experimental tool to study tolerance and education of immune cells. There is a vast literature 
where bone marrow chimaeras have been used to study T cell development, including 
positive and negative selection as well as peripheral mechanisms of tolerance [201-206]. The 
discussion here will focus on the use of bone marrow chimaeras to study regulation of NK 
cell development and tolerance. Already in 1977, Otto Haller et al. [207] showed that 
genetically determined levels of NK cell activity was a property intrinsic to the bone marrow, 
and not of the host, by doing crisscross bone marrow transplantation between MHC-I 
syngeneic mouse strains with high and low NK cell activity. Later, the generation of β2m-/- to 
B6 bone marrow chimaeras showed that NK cell missing self reactivity was determined by 
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the β2m-/- bone marrow [89]. In mixed allogeneic chimaeras, NK cells have been seen to be 
specifically tolerant to the donor and the host [208]. 
A role of the non-haematopoietic compartment for NK cells has also been shown. 
Transplantation of B6 x BALB/c F1 bone marrow into B6 hosts followed by assessment of 
rejection of lymphoid cells suggested that host cells rendered NK cells less responsive to B6 
cells [209]. Furthermore, bone marrow chimaeras where pure B6 or β2m-/- bone marrow or a 
mix of B6 and β2m-/- bone marrow was transplanted into irradiated B6 or β2m-/- hosts showed 
that presence of β2m-/- cells in the host or in the transplanted bone marrow rendered NK cells 
tolerant to the β2m-/- phenotype [105, 210]. In another study, mixed chimaeras were generated 
in B6 mice using B6 and β2m-/- bone marrow. The tolerance against β2m-/- cells was lost by 
NK cells, over time and the β2m-/- cells were rejected. The tolerance was broken even faster in 
the presence of MCMV infection, showing that inflammation can play a role in breaking self 
tolerance [39]. Recently, during the final part of the work in this thesis, Tovbis Shifrin et al. 
reported that haematopoietic and non-haematopoietic cells regulate NK cell tolerance 
differently. During infections, tolerance imparted by the non-haematopoietic cells is stronger 
than that induced by the haematopoietic cells [211]. 
In an attempt to assess and quantify the requirement for cells with a partial missing self 
phenotype in mixed bone marrow chimaeras, mixes of B6 (Dd-) and D8 (Dd+) bone marrow 
were transplanted to irradiated D8 hosts. The results suggested that presence of low numbers 
(<20%) of Dd- cells, reduced but failed to completely abrogate outgrowth of Dd- lymphoma 
cells [212]. This question was further investigated in the present thesis work.     
It should finally be noted that NK cell education and tolerance can be studied also in mice 
with mosaic MHC-I expression, e.g. where the haematopoietic (and non-haematopoietic) 
compartments are composed of cells with different MHC-I expression, despite being 
genetically identical and derived from the same zygotes. The mosaic DL6 model has already 
been briefly introduced in the section on NK cell education above. It will be described 
extensively in the results and discussion section, as it forms the basis of the major theme in 
this thesis. 
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2   AIMS  
General aim:  
To understand the influence of a perturbed sensing of MHC-I molecules in the host 
environment, on NK cell education for missing-self responses. In particular, to understand the 
effect of a mixed MHC-I expression in the environment as a model for optimizing NK cell 
based immunotherapy strategies in treatment of tumours.  
In order to approach this general objective, we have used transgenic and chimaeric mice as 
models for clinical situations where a mixed MHC-I host environment may occur, such as in 
bone marrow transplantation or adoptive transfer. More specifically, we have used transgenic 
mouse strains on H-2b (KbDb) background where a Dd transgene is expressed in all cells (D8 
and DL1 mice) or in a sub fraction of the cells (DL6 mice), as well as bone marrow 
chimaeras based on these strains. We were particularly interested in quantitative aspects of 
education, tolerance and responsiveness. Furthermore, we were interested in reactivity to 
three types of cells: those expressing a complete set of MHC-I genes (vis-à-vis the host) as 
well as cells lacking one MHC-I allele (the Dd transgene: “allele specific missing self” 
reactivity) and cells with no MHC-I expression at all (“general missing self responsiveness”).  
We have also used mice where perturbed MHC-I sensing of the environment is induced by 
antibody mediated blockade of inhibitory receptors on NK cells.  
Specific aims: 
The following specific aims emerged during the development of the work: 
•   To analyse the kinetics of the effects of perturbed MHC-I sensing via NK cell 
inhibitory receptor blockade on missing-self reactivity. 
 
•   To further characterize and develop a previously described transgenic mouse model 
(DL6) encompassing mosaic expression of an MHC-I gene (Dd) [92], and in 
particular, to identify mice with high frequencies (>85%) of Dd expressing cells. 
 
•   To develop refined in vivo assays for NK cell mediated rejection, to allow monitoring 
of three target cells simultaneously. 
 
•   To determine a quantitative threshold for NK cell tolerance to “allele specific missing 
self”, in terms of the minimal frequency of ligand deficient cells required to induce 
tolerance in hosts with mosaic MHC-I expression. 
 
•   To determine whether NK cell responsiveness against “general” missing self is 
influenced quantitatively by the proportion of cells with and without a given MHC-I 
ligand in mice with mosaic MHC-I expression. 
 
•   To determine whether mosaic MHC-I expression exclusively in the non-
haematopoietic host environment is sufficient to influence NK cell tolerance to “allele 
specific” missing self and “general” missing self responsiveness. 
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•   To establish a model for generation of mixed (Dd- vs. Dd+) bone marrow chimaeras 
with high frequencies (>85%) of Dd+ cells, and with NK cell function maintained. 
 
•   To determine whether mosaic/chimaeric MHC expression has a differential influence 
on reactivity towards normal vs. tumour cells, with respect to allele specific as well as 
general missing-self rejection. 
 
Afterwards, aims will be revisited and discussed in Concluding remarks and future 
perspectives (Section 4.10).  
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3   MATERIALS,  EXPERIMENTAL  TECHNIQUES  AND  
METHODOLOGICAL  CONSIDERATIONS  
The studies include immunological methods performed in experimental mouse models. 
Mixed bone marrow chimaeric mice as well as several transgenic mouse strains have been 
generated and used. Key methods used are multi parameter flow cytometry and in vivo assays 
such as target rejection assays, antibody blockade and bone marrow transplantation models. 
These murine models and experimental methods will be described in the following sections.  
3.1   MICE  
All mice were kept and bred under specific pathogen free conditions in the animal facility at 
the department of Microbiology, Tumour and Cell Biology, Karolinska Institutet, Solna 
Campus. 6-17 weeks old mice were used for experiments. Mice were age-matched for all 
experiments and age and gender-matched for bone marrow chimaeras. All experiments were 
performed according to ethical guidelines and were approved by Stockholms Norra 
djurförsöksetiska nämnd.  
C57BL/6 mice: Commonly denoted as B6 mice, they were obtained from the breeding unit at 
MTC, or purchased from Taconic Europe (Lille Skensved, Denmark). These mice have an 
MHC-I type of Kb Db.  
B6 b2m-/- mice: They lack the gene for b2m component of the MHC-I resulting in none or low 
expression of MHC-I on the cell surface [89]. 
DL6 mice: The DL6 mouse carries a fusion transgene a1/2Dd+a3Ld (induced via a vector 
construct pg24 [213]) on a B6 background, where it is expressed in a binary mosaic fashion 
i.e. varying fractions of cells are either positive or negative for the transgene. This is the main 
strain that has been generated and used for experiments performed for this study project. We 
have used this strain in homozygous as well as hemizygous state on a B6 background. We 
also generated a Ly5.1 variant for experimental purposes, as explained later. DL6 mouse is 
described in detail in the results section [92]. 
DL1 mice: This mouse, as described earlier [92], has the same fusion transgene (Dd+Ld) as 
the DL6 mouse, but with a global expression of the transgene, i.e. it is expressed on all cells, 
as opposed to the binary mosaic expression pattern in DL6 mice. Thus, it expresses an MHC-
I profile of Kb, Db and Dd molecules like the D8 mouse and both these strains have been used 
as controls for DL6 mice, during experiments. DL1 mice have been bred as backcrosses to 
B6 mice. By immunophenotyping for Dd, we determine the offsprings positive for the 
transgene, and use these mice for experiments and breeding.  
D8 (D8 Ly5.1) mice: The D8 mouse has been already described [214]. This mouse strain has 
an additional complete Dd transgene (α1, 2, 3) on a B6 background and, therefore, expresses 
an MHC-I profile of Kb, Db and Dd molecules. D8 mice have been used as control mice for 
DL6 experiments and chimaera experiments. They have also been used as donors and 
recipients for the mixed bone marrow chimaera and DL6 chimaera experiments, where a 
Ly5.1 variant, D8 Ly5.1 is also used to track cells from two different origins; donor and 
recipient.   
 28 
B6 Ly5.1 congenic mice: They were obtained from Charles River Laboratories, Lyon, 
France. We backcrossed most of the mouse strains used, with B6 Ly5.1 mice [215], and then 
intercrossed them to get the transgene and the Ly5.1 allele in the same mouse (ensured by one 
or more of the following methods, as applicable; blood immunophenotyping, genotyping, ear 
biopsies and test crosses). This was used for the purpose of tracking donor derived bone 
marrow cells in bone marrow chimaeras, generated as described below.  
3.2   BONE  MARROW  CHIMAERAS  
3.2.1   Mixed  bone  marrow  chimaeras    
These chimaeras were generated by transplanting D8 and B6 donor bone marrow into D8 
recipients. Prior to transplant of bone marrow cells, NK cell depletion was carried out in the 
donors and recipients to prevent NK cell mediated rejection. NK cell-depleting antibodies i.e. 
anti-NK1.1mAb (PK136) and anti-Tmb1 mAb (anti- CD122) were tested in pilot chimaeras 
with respect to dose, frequency and interval of depletion. It was noted that haematopoietic 
reconstitution of NK cells was better in recipients treated with anti-Tmb1 antibody, as 
compared to anti-NK1.1 antibody, which is an effective NK cell depleting antibody (perhaps 
due to a longer half-life of the latter antibody). Therefore, we decided that the donors and 
recipients were depleted of NK cells using different antibodies, the donors with anti-
NK1.1mAb (PK136 200µg Mabtech, Nacka, Sweden) and recipients with anti-Tmb1 mAb 
100µg, Mabtech, Nacka, Sweden). Depletion was performed 3-5 days before irradiation. 
Bone marrow cells were obtained from the hind limbs of NK depleted donor mice. The soft 
tissues were removed and the tibia, femur and ilium (pelvic bone) crushed and ground in PBS 
with EDTA, using a mortar and pestle. PBS was used to rinse the pestle and after filtering it 
through a 40µm mesh, filtrate was washes and re-suspended. T cell depletion was performed 
by negative selection using MACS anti-CD5 beads, MACS LD columns and MACS Midi 
magnets (Miltenyi, Bergisch Gladbach, Germany). T cell depleted bone marrow from 
different mouse strains was mixed to certain ratios (ratios between 50/50 and 25/75). The 
recipient mice received 137Cs irradiation split into 2 doses i.e. 500 and 600 rad, 4 hours before 
transplant. Each mouse received 10x106 bone marrow cells via an intravenous injection in the 
tail vein. Mice received antibiotics (Trimethoprim Sulfadazine 0.2/1mg/ml) in drinking water 
for 3-5 weeks. Reconstitution was checked by immunophenotyping blood at three time 
points; early (day 7-11), middle (day 30-35), late (day 48-55) to assess the kinetics of 
haematopoietic reconstitution. Mice were used in experiments 8-10 weeks post-transplant, 
based on our unpublished results showing that NK cells become mature and functional 
around 8 weeks after transplant.  
3.2.2   Bone  marrow  chimaeras  in  MHC-­I  mosaic  recipients  
These chimaeras were generated by inoculating D8 donor bone marrow into DL6 mosaic 
recipients. The protocol was the same as described for the mixed bone marrow chimaeras, but 
with some differences. No NK cell depletion of recipients was done, as the MHC phenotype 
of the donor cells was already present in the recipients and NK cells were tolerant.  Neither 
were donor NK cells depleted, since they could eliminate the remaining recipient Dd- 
haematopoietic cells, thus allowing for better reconstitution. The donor bone marrow was not 
depleted of T cells either, as there were no additional MHC molecules in the recipients, both 
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donors and recipients were of the same gender and we did not expect any T cell reactivity. 
Thus, rejection was not expected in any direction, in this MHC-I setup. Since every mouse 
group received only one kind of bone marrow, these are not mixed bone marrow chimaeras.  
3.3   TUMOUR  CELL  LINES  
Tumour cell lines were cultured in vitro or grown as ascites in vivo, depending upon the 
amount of cells required (culture conditions- 7% CO2 at 37oC, in RPMI 1640 medium 
supplemented with 10% heat-inactivated FBS, 100U/ml Penicillin, 100mg/ml Streptomycin, 
2mM L-glutamine, 50mM 2ME, 1mM sodium pyruvate, non-essential amino acids). For in 
vivo growth, suitable mice were selected to avoid any rejection of the tumour cells, and 
irradiated sublethally (4 Gy). Frozen tumour cell lines were thawed, inoculated 
intraperitoneally in mice and grown as ascites for about a week. Mice were then assessed by 
abdominal palpation for ascites growth, and sacrificed after around 7 days. Peritoneal lavage 
was performed with PBS and on average ~500 x106 cells were recovered from a mouse. The 
lavage was filtered and washed with PBS to reduce coagulates and cell lysis by enzymes. 
Ascites has been used instead of in vitro cell cultures because here the cells grow in more 
physiological conditions and there is no cell activation that is otherwise induced in the cell 
cultures by the use of additives e.g. growth factors required for the cultures to maintain 
growth. Also, the cell yield is more in ascites, which is a requirement for in vivo challenge 
assays.  
RMA: RMA (H-2b) is a sub-line of Raucher virus-induced EL-4 T cell lymphoma of B6 
origin. [78] [216]  
RMA-S: RMA-S is a TAP-2 deficient variant of RMA [217]  
RBL-5Dd: RBL-5Dd is EL-4 transfected with the vector pDd-1 encoding genomic H-2Dd 
[218]. RBL-5 and EL-4 are identical, where RBL-5, RMA and RMA-S are all derived from 
EL-4.  
C1498: It is a mouse H-2b NKT tumour cell line [219], and was a kind gift from Andrew 
Makrigiannis, Dalhousie University, Canada. C1498- is a MHC-I- variant of the original 
MHC-I+ tumour. [74].  
3.4   IMMUNOPHENOTYPING  
3.4.1   Preparation  of  cells  
Preparation of cell suspensions from spleens for immunophenotyping:  
Spleens were mashed in petri dishes using plungers. The cells in the petri dishes was rinsed 
out with PBS and thereafter pelleted in 15 ml falcon tubes. Erythrocyte lysis was performed 
with either ER lysis buffer (ACK, containing NH4Cl) and stopped by the addition of 10 times 
the volume of PBS, or with ddH2O and stopped with 10x PBS. Lysate was filtered through 
40µm nylon mesh strainers and after washing, re suspended in PBS. 1-1.5x106 spleen cells 
were added per well in a 96-well v-bottomed plate. After centrifuging to pellets, staining 
solutions were directly added to cell pellets and mixed.  
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Preparation of cell suspensions from blood for immunophenotyping:  
100µl of heparinized blood was added per well in a 96-well v-bottomed plate. After pelleting, 
200µl of BD lyse buffer (BD Biosciences, New Jersey, USA) diluted 10 times in ddH20 was 
added, and samples incubated at room temperature for 20 minutes. This step was repeated 
once more and blood was pelleted by centrifugation. Staining solutions were added directly to 
pellets and mixed. 
3.4.2   Cell  surface  staining  
Cells were stained with titrated concentrations of antibodies diluted in PBS (sometimes in the 
presence of 0.5% FBS) and incubated in the fridge (4oC) or on ice, usually for 30 minutes. 
This was followed by washing steps and resuspension in PBS. Sequentially, Fc receptors 
were blocked using a blocking antibody anti-CD16/32 (2.4G2), followed by surface staining. 
Cells were either unfixed and analysed within 4 hours on the same day, or fixed (in 1% PFA) 
and analysed the next day.  
3.4.2.1   Typing of mice 
The DL6 mice were typed before planning experiments to find out the percentages of Dd+ 
fraction in each mouse. Blood was immunophenotyped using an antibody against the Dd (α1, 
2) domains of the fusion transgene Dd+Ld (34-5-8S PE-conjugated, BD Biosciences, New 
Jersey, USA.). Blood from mice with complete Dd expression (D8, DL1) or no Dd expression 
(B6, b2m-/-) was used as control in the experiment. The method was same as for surface 
staining.  
3.4.2.2   Multi-colour panels 
These were designed using multiple antibody combinations to study NK cell features like 
receptor repertoire, maturation subsets etc. Care was taken to properly control for variables 
e.g. fluorochrome instability, dead cell exclusion, doublet exclusion, fluorescence minus one 
controls, fidelity controls, etc., along with compensation controls.  
3.4.3   Flow  cytometry  
FACS Scan, FACS Calibur and LSRII SORP (Becton Dickinson, New Jersey, USA) flow 
cytometers were used. Cells were acquired using Cell Quest or Diva (BD Biosciences) 
softwares, at 3,000-10, 000 events/ second, depending on the machine and assay. Analyses 
were done using Cell Quest Pro or Flowjo (9.6, 10 Tree Star, Oregon, USA) softwares. 
3.4.4   Antibodies  
The following antibodies were used in flow cytometry.  
From Biolegend, San Diego, USA 
anti-NK1.1 (PK136, mouse IgG2) 
anti-Dd (34-5-8S) 
anti-CD3e (145-2C11) 
anti-NKp46 (29A1.4) 
anti-CD49b (DX5) 
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anti-Ly49A (YEI/48 A1) 
anti-Ly49G2 (4D11) 
anti-KLRG1 (2F1/KLRG1) 
anti-2B4 (m2b4 (B6) 458.1) 
anti-CD69 (HI.2F3) 
anti-KLRG1 (2F1/KLRG1) 
anti- CD107a (ID4B-RUO) 
anti-IFN-γ (XMG1.2) 
anti-CD45.1 (A20) 
anti-CD45.2 (104) 
From R&D systems, MN, USA.  
anti-Ly49D (4E5) 
anti-Ly49I ((YLI-90) 
anti-NKG2D (CX5) 
anti-CD27 (LG.3A10) 
anti-CD11b/Mac-1 (M1/70.15) 
anti-CD49b (DX5) 
anti-Ly49C/I (5E6) 
From BD Biosciences, New Jersey, USA 
anti-Fcg RII/III receptor blocking antibody (anti CD16/32, 2.4G2) 
anti-H2-Dd-PE (34-5-8S) 
 
Streptavidin-QD605 (Invitrogen Molecular Probes) 
Live/Dead Fixable Aqua Dead cell stain kit (Molecular Probes, Invitrogen, Oregon, USA) 
anti-IgG 3 anti-mouse IgG3 (Southern Biotechnology, Alabama, USA) 
anti-NKG2A/C/E (20d5) (AbD Serotec, Oxford, UK) 
anti-Ly49C (4LO3311 hybridoma) (kind gift from Suzanne Lemieux, Institut Armand-
Frappier, Quebec, Canada) 
3.5   IN  VIVO  ASSAYS  
3.5.1   Spleen  and  tumour  cell  challenge  assays  
3.5.1.1   Two cell assay/CFSE assay 
Cells were labelled with two concentrations of the fluorescent dye Carboxyfluorescein 
succinimidyl ester (CFSE, Molecular Probes, Invitrogen, Oregon, USA.). One cell type was 
the internal control, expected to be retained by all recipient mice and the second cell type was 
the test (which we were interested in studying rejection of). Cell suspensions were prepared 
from spleens (normal cells)/ascites (tumour cells), and counted, as described above, under 
sterile conditions. The CFSE stock solution (10µM) was thawed in dark and two labelling 
concentrations i.e. 5µM (usually for test cells) and 0.5µM (usually for control cells) were 
prepared in PBS. Cells were carefully mixed with the corresponding labelling solution to 
 32 
ensure a uniform labelling intensity. Labelled cells were incubated at 37oC for 10 minutes and 
then washed with 10 times the volume of ice cold PBS with 20% FBS (foetal bovine serum). 
After filtration, cells were counted and re-suspended in PBS (at a final concentration of 
200x106 cells/ml in case of spleen cells and 300x106 cells/ml in case of tumour cells. Equal 
volumes of the two labelled cell solutions were mixed. Finally, 0.1ml of the solution mixture 
(containing 20x106 spleen cells/30x106 tumour cells) was injected intravenously in the tail 
vein of each mouse. Some of the mixture was analysed by flow cytometry to get an 
inoculated ratio between the two labelled cell types. For kinetic analysis in case of spleen cell 
assay, blood was drawn on days 1, 3 and 4 or on days 2 and 4. On day 4 the mice were 
sacrificed and spleens were also analysed by flow cytometry for a final readout. For tumour 
cell assay, no blood was drawn and only the spleens were analysed 8-36 hours after injection 
(as indicated). The final ratio between the two labelled cell types was corrected for the 
inoculated ratio. The results were expressed as percent labelled test cells out of total cells in 
the spleen, or as ratio of survival of the test cells corrected for the inoculated ratio, using the 
following formula.  
relative survival of test cells = (% remaining test cells/% remaining control cells)/ (% test 
cells in inoculate/% control cells in inoculate) 
3.5.1.2   Three cell assay/CFSE+Violet assay 
 
This method was developed during this thesis work. It is a modification of the two 
cell/CFSE assay, where one control cell and two test cell populations were inoculated and 
studied in vivo. The additional test cell type was labelled with the cell tracking dye BMQC 
Violet (Molecular Probes, Invitrogen, Oregon, USA). Staining concentration was 
determined as 10µM by titration experiments as described in results section. To 
accommodate 3 cell populations, the cells were re-suspended at a final concentration of 
about 300x106 cells/ml in case of spleen cells and 450x106 cells/ml in case of tumour cells. 
Finally, 0.1ml of the solution mixture (containing approximately 30x106 spleen 
cells/45x106 tumour cells) was injected intravenously per mouse and the readout was done 
as described above but with 2 control/test cell ratios in this case.  
3.5.2   NK  receptor  blocking  assays  
 
Intra-peritoneal inoculation of 5E6 F(ab’)2 fragments specific for Ly49C/I (Novo Nordisk, 
Denmark) was done to block self-specific inhibitory NK cell receptors. After 16 hours-7 
days, mice were challenged by intravenous inoculation of fluorescently labelled β2m-/- 
spleen cells and RMA lymphoma cells, and measurement of rejection was done. The 
readout for the two independent cell types was shown as percent labelled test cells out of 
total cells in the spleen.  
3.5.3   Intra-­peritoneal  assay  
C1498+ (MHC-I+) and C1498- (MHC-I-) tumour ascites were obtained from mice. CFSE 
labelled tumour cells were mixed with NK1.1 depleted BMQC Violet labelled syngeneic 
cells from impaired missing-self recognition (IMSR) mice [220] as reference cells, and 
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inoculated intraperitoneally as a mixture. Readout was done 6 hours later in spleens. Naïve, 
NK depleted and Poly I:C (Sigma, Missouri, USA) activated mouse groups were used.  
3.6   STATISTICS  
Data from flow cytometry were obtained and plotted using Microsoft Excel and GraphPad 
prism 6.0 (California, USA). Results were shown as data for individual mice or as group 
means with standard deviation. Dunnett’s test for multiple comparison was applied when 
comparing different groups. The p-value of less than 0.05 was considered as significant. 
Pearson’s correlation coefficient or r was also determined for measuring strength of linear 
associations.   
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4   RESULTS  AND  DISCUSSION    
4.1   PERTURBED  MHC-­I  SENSING  BY  NK  CELL  INHIBITORY  RECEPTOR  
BLOCKADE  
Studies have shown that adoptive transfer of activated NK cells with missing-self activity 
towards the host can, in certain settings, have a corresponding beneficial anti-leukaemic 
effect [154] [221]. In previous studies by our group and others (reviewed in the introduction), 
it has been explored whether the same beneficial anti-tumour effect can be achieved in an 
autologous situation where MHC-I sensing is perturbed. In the study by Vahlne et al. [168], 
an in vivo scenario mimicking missing-self recognition was achieved by antibody mediated 
blockade of certain NK inhibitory receptors. The Ly49C/I receptors expressed by 34-60% of 
NK cells in the B6 strain, were targeted using F(ab’)2 fragments of a blocking antibody from 
the hybridoma 5E6. Upon challenge with fluorescently labelled MHC-I sufficient spleen cells 
and tumour cells (RMA lymphoma cells), the tumour cells were more efficiently eliminated 
by NK cells of the antibody treated mice, while self tolerance to spleen cells was maintained. 
No signs of autoimmunity were observed.  
Considering the importance of self MHC-I-inhibitory receptor interactions in NK cell 
education (as discussed in introduction), the same setting was explored to study the functional 
maturity of developing NK cells and the retuning potential of mature NK cells. We reasoned 
that the robust tolerance to normal cells might be explained if one assumes that prolonged in 
vivo blockade of inhibitory receptors leads to a re-adjustment of NK cell activation threshold 
in order to avoid autoreactivity, in line with the predictions of the “rheostat model”. An 
implication of this hypothesis and reasoning was that NK reactivity to normal cells 
representing missing self should be decreased by inhibitory receptor blockade, even if the 
killing of MHC-I expressing tumour cells was increased. We tested this prediction in studies 
led by Stina Wickström, a colleague in the group. This project was part of a bigger study, in 
which another approach to test possible “retuning” effects was also used: adoptive transfer of 
NK cells between mice with different MHC-I genes [222].   
In the studies of antibody blockade, we were particularly interested in testing the kinetics of 
possible retuning effects, as measured by reduced rejection of MHC-I deficient, but otherwise 
normal spleen cells. Different groups of B6 mice were given intra-peritoneal inoculation of 
5E6 anti-Ly49C/I F(ab’)2 (at various time points) and then challenged by intravenous 
inoculation of fluorescence labelled syngeneic B6 spleen cells, β2m deficient spleen cells and 
MHC-I expressing syngeneic tumour cells (RMA lymphoma). We measured the survival of 
each of these target cells in parallel in a short term assay. We reasoned that two different 
effects of inhibitory receptor blockade might have distinct kinetics: the blockade in the 
effector/target interaction resulting in increased killing of MHC-I+ lymphoma cells would 
occur rapidly within hours, while the retuning effect would take longer, perhaps several days.  
The experiments showed that while the inhibitory receptor blockade with 5E6 anti-Ly49C/I 
F(ab’)2 increased in vivo NK mediated killing of MHC-I expressing lymphoma cells (Figure 
4; [168]), it did indeed reduce the killing of β2m deficient, but otherwise normal spleen cells, 
as predicted by the hypothesis. In contrast, in mice treated with a control antibody binding a 
non-self specific inhibitory receptor (4D11 binding Ly49G2), killing of β2m deficient spleen  
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cells was unaffected (Figure 4A-C). MHC-I expressing spleen cells were not killed in vivo by 
NK cells, regardless of whether the mice had been treated with 5E6 anti Ly49C/I F(ab’)2 or 
not (Figure 4A). Killing of MHC-I deficient tumour cells was, however, maintained, as 
examined by the challenge with two independent tumour cell lines: RMA-S and C1498 
MHC- (Figure 4D-F). Our interpretation is that the reduced killing of MHC-I deficient spleen 
cells reflects a “retuning” imposed by the reduced inhibitory input after receptor blockade. 
We further speculate that this retuning would maintain tolerance to normal cells, but would 
still allow killing of tumour cells due to their higher expression of ligands for activating NK 
cell receptors.  
Figure 4. Inhibitory receptor blockade reduces rejection of normal cells, but not tumour cells. A–
F, CFSE-labelled cells were inoculated i.v. into B6 mice that were untreated or treated with the 
indicated blocking reagent alone or in combination with depleting anti-NK1.1 mAb. Results are 
displayed as mean surviving target cells in percentage of total spleen cells (A–E) or as a ratio of 
target cells versus control cells (F). A–E, 5E6 (F(ab’)2 binding to Ly49C/I) or 4D11 (F(ab’)2 
binding to Ly49G2) with or without anti-NK1.1 mAb was administered i.p. 48 hours before 
CFSE-labelled B6 (A), ß2m-/- (A and B), RMA (D), or RMA-S (D and E). A–E, cell suspensions 
were inoculated i.v. and survival of target cells was analysed 44 hours (A–C) or 24 hours (D and 
E) later in the spleen. F, C1498-MHC- cell suspension was coinjected i.p. with MHC I+ NK cell-
depleted control spleen cells. Six hours later, survival of target cells was analysed by peritoneal 
lavage. The survival ratio of the parental MHC I+ C1498 line was 1.37±0.5 in B6 and 1.68 ± 0.8 in 
NK1.1-depleted B6 mice (P = 0.4977). A shows one representative experiment out of five, with 4 
mice per group, B shows a compilation of five experiments with a total of at least 17 mice per 
group, and C shows a compilation of three experiments with at least 11 mice per group except the 
NK1.1-treated group, which had 6 mice in two experiments. D shows 4 mice per group, one 
representative out of two independent experiments, E shows a compilation of two experiments 
with a total of 8 mice per group, F shows three experiments with 8 mice per group except for the 
NK1.1-treated group, which has 4 mice. Error bars, SD. Statistically significant differences are 
denoted: *, P < 0.05; **, P < 0.01; ***, P < 0.001; ns, not statistically significant. (Reproduced 
with the permission of the publisher). 
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Surprisingly, the induction of reduced killing of normal MHC-I deficient cells did not require 
several days; it was observed reproducibly within 24 hours and often as early as after 16 
hours of receptor blockade, indicating that the retuning is a fairly rapid process (Figure 5). 
Despite several attempts using the two targets in the same mice, we were not able to 
distinguish a reproducible kinetic difference between this process and the one resulting from 
the action of inhibitory receptor blockade in the effector target interaction leading to 
increased killing of MHC-I+ lymphoma cells (Figure 5). One reason for this may be the poor 
time scale resolution of this type of assay, which uses 24-48 hours to monitor the end point 
effect of retuning, i.e. in vivo killing of normal cells.  Future studies should address the 
kinetics of retuning using a shorter assay allowing also specific monitoring of the targeted 
NK cell subset (Ly49I and Ly49C expressing NK cells), e.g. the in vitro single NK cell 
responsiveness assay measuring degranulation (CD107α) and cytokine production (IFN-γ) 
after stimulation with plate bound antibodies against activating NK cell receptors. In our 
published study [222], it was also demonstrated that the Ly49I (but not the Ly49C) single 
positive NK cells were indeed rendered hyporesponsive by the antibody blockade, but the 
kinetics of this effect were not explored. 
In these experiments, we could thus confirm that NK cell education for missing self rejection 
can be influenced rapidly by perturbed sensing of MHC-I in the host environment. The 
results are highly relevant to similar NK inhibitory receptor blockade in clinical trials, 
because although we observed a beneficial effect on tumour cell killing, it cannot be excluded 
that this was a net effect that would have been more impressive if it had not been influenced 
by a general retuning of NK cell responsiveness. It has indeed been recently reported by 
Carlsten et al. that also in humans, antibody-mediated blockade of inhibitory receptors 
(KIR2D) leads to hyporesponsiveness of targeted NK cells, demonstrated by the observation 
that KIR2D single positive NK cells showed a reduced responsiveness to K562 tumour cells 
in vitro after receptor blockade. Furthermore, in this clinical phase II trial including nine 
patients with smouldering multiple myeloma, no clinical benefit of the treatment could be 
demonstrated [223]. In future studies of inhibitory receptor blockade, it will be important to 
explore different doses and administration regimens of the blocking antibody, in order to 
optimize the effects on the effector-tumour target interaction, and minimize the retuning 
effect that presumably occurs during continuous interactions between NK cells and normal 
cells.  
The experimental situation tested in the studies above involved reduced general sensing of 
MHC-I on all cells in the host, at least by one particular NK cell subset. However, the results 
have implications also for other clinical situations where MHC-I sensing is perturbed in a 
fraction of the cells in the host environment, i.e. in situations of host/donor chimaerism. We 
reasoned that such a heterogenetic environment may have similar effects on NK cell 
education and tolerance, and in particular, that influence may depend on the degree of 
chimaerism. We thus set out to investigate quantitative aspects of education for missing-self 
recognition in different models for MHC-I chimaerism/mosaicism.  
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Figure 5. Kinetic analysis of effects on rejection capacity after inhibitory receptor blockade. A-
E. CFSE-labelled cells were inoculated i.v. into B6 mice that were untreated, treated with 5E6 
blocking reagent or with depleting anti-NK1.1 mAb (A-E), or ß2m-/- control mice (D-E). Results 
are displayed as mean surviving target cells in percentage of total spleen cells. 5E6 F(ab’)2 was 
administered i.p. at indicated time points before CFSE-labelled ß2m-/- (A, B and D) or RMA (C 
and E) cell suspensions were inoculated i.v. and survival of target cells was analysed 48 hours 
(A-C) or 44 hours (D-E) later in the spleen. Three individual experiments are shown (A, B-C 
and D-E respectively) with 3 mice per group. Error bars, SD. Statistically significant differences 
are denoted: *, P < 0.05; **, P < 0.01 (D-E).  
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4.2   CHARACTERISTICS  OF  DL6  MICE  WITH  MOSAIC  EXPRESSION  OF  AN  
MHC-­I  GENE  
4.2.1   Previous  studies  of  DL6  mice  
DL6 mice were briefly introduced above as the first model to provide evidence for reversible 
education of NK cells. These mice show a mosaic MHC I transgene expression, with cells of 
two different phenotypes: KbDbLd/Dd and KbDb. These mice were identified in a transgenic 
line on B6 background (providing Kb and Db genes), into which an engineered Dd gene (with 
α3 domain from Ld and α1/α2 domains from Dd) had been introduced. This Ld/Dd chimaeric 
MHC-I gene product functioned as the wild type Dd gene with respect to recognition by NK 
cell inhibitory receptors, as shown with transfected target cells [224-226] and also with 
another transgenic line on B6 background, (DL1), where the transgene was expressed as a 
normal MHC-I gene, i.e. in all cells [225]. In DL1 mice as well as in D8 mice (wild type Dd 
transgene on B6 background), NK cells recognized cells lacking Dd as “missing self” [92, 
218, 227, 228]. For simplicity, this chimaeric gene used to generate DL1 and DL6 mice will 
therefore be referred to as Dd in the remainder of the text. A summary of the mouse strains 
used in the study is shown in Table 2. 
 
 
 
Johansson et al. studied how the mosaic MHC-I expression in DL6 mice affects the education 
of NK cells, in particularly whether cells lacking the Dd ligand would be recognized as 
“missing self” also in these mice [92]. The methodology included in vitro NK cytotoxicity, 
bone marrow transplant rejection and measurements of tumour outgrowth. These assays 
showed a complete tolerance against cells lacking the critical MHC-I Dd molecule in all 
mosaic mice. However, the tests used did not allow a quantitative analysis of rejection 
capacity, in particular the in vivo assays where the simple end point was either growth or 
rejection. More quantitative assays were needed in order to appreciate the kinetics and 
magnitude of rejection, and to get a picture of NK cell tolerance to normal cells of not only 
tumours but also healthy spleen cells in vivo, without having the need to activate NK cells 
priorly and artificially. This was particularly important in view of the emerging models on 
NK cell education and tolerance, highlighting quantitative aspects (i.e. the rheostat model 
discussed above), and the methods becoming available to study that, including in vivo 
cytotoxicity assays as developed in the previous section. An additional reason to revisit the 
DL6 model was that very few mice in the initial studies showed a proportion of Dd+ cells 
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higher than 75%. We reasoned that the breaking of tolerance to missing self might require a 
very high proportion of such cells, and we hoped to find this if we tested large amounts of Dd 
homozygous DL6 mice, which had not been done in previous studies.  
Offspring from breeding of homozygous DL6 mice were immunophenotyped by flow 
cytometric analysis of blood cells using anti-α1α2-Dd -PE antibody. All DL6 mice had a 
mixture of Dd positive and negative cells albeit in varying proportions. Examples of 
histograms from immunophenotyping of individual mice are shown in Figure 6. Non-
transgenic B6 control mice showed less than 1% while D8 and DL1 showed more than 97% 
cells in the Dd positive gate. In earlier studies [92], it was confirmed that all mice in the 
backcrosses who had inherited the transgene (as determined by Southern blot) also expressed 
it in at least a fraction of the blood cells. 
 
 
 
4.2.2   Dd  expression  pattern  in  different  crosses  and  breeding  lines  of  DL6  
mice  
We typed more than 1300 mice carrying the Dd/Ld transgene in homozygous or heterozygous 
form in the present study. The breeding crosses performed, in general, confirmed the 
observations made in the earlier studies [92] concerning inheritance and expression patterns. 
Figure 6. DL6+/+ mice show variable frequencies of Dd+ cells in peripheral blood. Peripheral blood 
lymphocytes were stained for Dd and analysed by flow cytometry. Plots show data gated on 
lymphocytes, from three individual DL6 mice in the top panel and control mice B6, DL1 and D8 
in the bottom panel. The fraction of Dd- and Dd+ cells are shown in the respective histograms. 
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The transgene was thus inherited and expressed as a single (autosomal) dominant gene, i.e. all 
mice in F1 crosses of DL6 mice expressed the transgene and in backcrosses of such mice to 
B6 mice 50% expressed the transgene. The transgene was always expressed only in a fraction 
of the blood cells (10-80%). The proportion was roughly the same in T cells, B cells, NK 
cells as well as in fibroblasts. It should be noted that the latter had a low MHC-I expression in 
general and appeared negative for all molecules, including Kb and Db. After exposure to IFN-
γ for 48 hours, most of the fibroblast became positive for Kb and Db while the staining pattern 
for the Dd transgene appeared mosaic in a similar fashion as the lymphocytes (data not 
shown).  
The proportion of Dd+ cells in peripheral blood remained stable within each mouse when 
followed over time. In the present study, we tested directly whether the mosaic expression 
pattern was determined at the RNA level. Dd+ and Dd- cells from the spleen were separated by 
flow cytometry and mRNA for Dd was assessed by PCR. Only Dd+ cells showed presence of 
the transcript (data not shown). 
The fraction of transgene expressing cells varied between the mice within each litter along 
the same range as between litters. The transgene was expressed in a similar fashion in female 
and male mice, arguing against X chromosome inactivation as a mechanism to explain the 
mosaicism. Furthermore, the fraction of cells expressing the transgene was independent of the 
sex of the parent transmitting the transgene, the fraction of expressing cells in the transmitting 
parent and whether the proband was heterozygous or homozygous for the transgene (no 
parental imprinting). 
We reasoned that a first simple possibility to identify mice with very high frequencies 
(>80%) would be to type many DL6 mice, thus increasing the chance to find the extremes. In 
the present study we typed 861 homozygous DL6 mice and observed that the frequency of 
Dd+ cells varied from 8 to 93% (Figure 7). The mean frequency was 43%. Homozygous DL6 
mice were crossed to B6 mice, to generate Dd hemizygous mice (169) in order to repeat, and 
compare to earlier DL6 studies that had been carried out on hemizygous DL6 mice. The 
frequencies of Dd+ cells largely overlapped with those of homozygous DL6 mice, but there 
was a lower maximum frequency (78%) and a lower mean frequency of Dd+ cells i.e. 37%.  
In the previous study, the frequency of Dd+ cells ranged between 10% and 80%. It was 
particularly interesting for us to identify mice with a very high frequency of Dd+ cells in 
which we could study tolerance towards Dd- cells. To our disappointment, only a few mice 
had more than 90% of Dd+ cells, as seen in the distribution in Figure 7. However, by 
coincidence, we obtained mice with a distribution skewed towards higher frequencies of Dd+ 
cells in a cross where DL6 mice were bred to B6 Ly5.1 mice. This cross was originally made 
to utilize the (CD45.1/2) Ly5.1/5.2 system to track transplanted cells in bone marrow 
chimaeras. When we typed the Ly5.1 DL6 mice (n=261), we unexpectedly found that these 
showed higher frequencies of Dd+ cells, ranging from 59% to 97% and a mean frequency of 
73% (Figure 8). 
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Figure 7. Distribution of frequencies of Dd+ cells in peripheral blood of individual DL6+/+ 
mice. Peripheral blood lymphocytes were stained for Dd and analysed by flow cytometry. 
Individual mice divided, based on frequency of Dd+ cells, in 5% increments and shown as a 
histogram. n=861. 
Figure 8. Distribution of frequencies of Dd+ cells in peripheral blood of individual mice from 
different DL6 breedings. Data from flow cytometry analysis, figure shows DL6+/+ (n=861), DL6+/- 
(n=169) and DL6+/+ Ly5.1 (n=261). Error bars, SD. Statistically significant differences are 
denoted: ****, P < 0.0001 
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4.2.3   Cell  surface  expression  levels  of  the  Dd  transgene  
The Dd cell surface expression levels/fluorescence intensity (MFI) in Dd homozygous DL6 
mice was slightly higher than that of hemizygous DL6 mice (Figure 9), showing that Dd 
molecule intensity of expression might be relative to mono- or bi-allelic expression of the Dd 
transgene. There was thus, no apparently strong gene dose effect at the level of cell surface 
expression, similar to observations in mice carrying the wild type Dd transgene on B6 
background (i.e. where Kb and Db is co-expressed, data not shown). In contrast, there is a 
clear difference in Dd cell surface expression when the Dd wild type transgene is expressed in 
homozygous vs. hemizygous form in the absence of any other MHC-I genes, in ‘Dd single 
mice’ [98]. The absence of a clear-cut Dd gene dose effects in DL6 mice expressing the 
transgene on B6 background, had one important practical consequence: it was impossible to 
type for mono- versus bi-allelic expression in the gene backcrosses where both of these 
outcomes were possible.  
 
 
 
4.2.4   Possible  genetic  mechanisms  behind  the  expression  patterns  of  the  Dd  
transgene  in  DL6  mice  
Mosaic or variegated gene expression patterns have been described previously, both for 
natural genes and transgenes [229]. It may be that this expression pattern is “under 
diagnosed” in transgenic settings, since mice in such studies are often typed exclusively in 
assays that do not allow for analysis at the single cell level. It should be noted that not only 
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Figure 9. Cell surface expression levels of Dd in peripheral blood of individual mice from 
different breedings. Data from flow cytometry analysis, figure show geometric mean 
fluorescence intensity (MFI) of Dd staining in D8 (n=2), DL1 (n=6) DL6+/- (n=18), DL6+/+ 
(n=38). Error bars, SD. Statistically significant differences are denoted: *, P < 0.05; **, P < 0.01 
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was there mosaic expression of the transgene, the degree of mosaicism varied between the 
mice within the same litters of the inbred homozygous DL6 strain. The most likely 
interpretation for this expression pattern is that the site of integration of the transgene makes 
it prone to epigenetic inactivation (or activation) early during embryonic development [92]. 
Stochastic variations in the junctions between active and inactive chromatin may then lead to 
differences in expression pattern between individual mice, similar to position effect 
variegation described in Drosophila [230]. If this is determined in an irreversible fashion 
early during development, it may lead to a stable proportion of transgene expressing cells in 
most or all cell lineages within the same mouse, but different between mice in the same litter. 
How can one then explain the distribution of frequencies of Dd+ cells in the Ly5.1 DL6 mice? 
One speculation is that the flanking regions of the Ly5.1 (CD45.1) gene (originally derived 
from the SJL strain [215]) contain genes coding for factors involved in regulation of 
transcription or epigenetic regulation. Indeed, biological differences between the congenic 
Ly5.1 and Ly5.2 B6 strains have been reported [231, 232]. The backcrosses to B6 Ly5.1 mice 
might thus have introduced a factor that influences the probability for expression of the Dd 
transgene, skewing the distribution towards higher frequencies of Dd+ cells. Other 
possibilities are not excluded and further analyses are required.   
4.2.5   Potential  influence  of  downstream  cellular  interactions  on  the  
frequency  of  Dd+  cells  in  DL6  mice  
Considering all typed mice within the different breeding lines, we observed a range between 
8% and 93% with respect to the frequency of Dd+ cells. This observation imposed some 
practical limitations for the purpose of our study, where mice at both extreme ends were 
interesting. The observation also stimulated us to speculate about the implications of the 
absence of mice with frequencies of Dd+ percentages below 8% and above 93%. Could this 
expression pattern also be influenced by events downstream of gene regulation, including 
immune mechanisms highly relevant to our studies?  
Regarding the upper end of the range, one of the possible outcomes in mice with a higher 
frequency of Dd+ cells was that NK cell tolerance to Dd- cells would be obliterated, leading to 
further shrinkage of the Dd- component due to NK cell mediated killing. In that case, one 
would observe a frequency range of Dd+ cells approaching and capping at around 80/85%, 
beyond which the mice would express no Dd- component due to rejection. Instead, there 
would be a peak at the highest end of the range i.e. 100% (or just below 100%) Dd+ cells, 
giving rise to a bimodal distribution. This, however, was not seen, corroborating the 
observation that the Dd- component, irrelevant of its size, maintains itself and drives 
tolerance/coexistence of the two cell types which are phenotypically different with respect to 
MHC-I.  
Conversely, we speculated about the possibility that in DL6 mice with low frequency of Dd+ 
cells, NK cell as well as T cell tolerance to Dd+ cells might be obliterated. In line with the 
reasoning above, we would then expect the opposite bimodal distribution, with no mice 
showing proportions of Dd+ cells below the critical threshold, and then higher numbers of 
mice with no Dd+ cells at all.  However, this was not observed, and the data thus suggest that 
tolerance towards Dd is maintained even when very few cells express this MHC-I molecule.  
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Finally, we have considered the possibility that foetal abortion of offsprings with more 
extreme frequencies of Dd+ cells (positive or negative) might explain the observed 
distributions of expression. Such a spontaneous abortion pattern might be related to immune 
or other mechanisms. However, the litter sizes remain comparable to other breedings (e.g. 
DL1 and D8 mice, data not shown). As already mentioned, no indication of the influence of 
maternal frequency of Dd+ cells on the corresponding offsprings’ frequencies have been 
observed. 
Altogether, the data thus suggest epigenetic regulation as a mechanism behind the expression 
patterns of the Dd gene in the DL6 mice. More studies are required to understand the 
regulation of this transgene, and this goes beyond the scope of this thesis.  
Regardless of the mechanism, the DL6 model provided a tool to realize a quantitative way to 
address NK cell education, tolerance and tumour reactivity with respect to allele specific 
missing self as well as general missing self, in the context of normal as well as tumour cells. 
This required methods to study NK cell mediated rejection of several target cells in vivo 
simultaneously, which is the subject of the next section. 
4.3   REFINED  IN  VIVO  ASSAYS  FOR  NK  CELL  MEDIATED  REJECTION  OF  
MULTIPLE  TARGET  CELLS  
4.3.1   Development  of  an  assay  to  measure  rapid  in  vivo  elimination  of  three  
target  cells  simultaneously  
One of the major uses of the assay for short term rejection of fluorescence labelled target cells 
(hereafter called short term rejection assay) in the context of NK cell education studies, is to 
assess missing self induced rejection in vivo, usually by comparing a test population (MHC-I 
deficient) to a control population (MHC-I sufficient). In the DL6 mosaic mouse, however, we 
have two MHC-I phenotypes, KbDbDd and KbDb, and this required a refined test. We needed 
to study three different target cells: one with complete ‘missing-self’ phenotype (MHC-I 
deficient, representing general missing self responsiveness), one lacking only the Dd allele 
(still expressing Kb and Db, representing allele specific missing self rejection) and one control 
expressing the complete MHC-I phenotype, Dd along with Kb and Db. We used spleen cell 
targets from MHC transgenic and knockout mice as well as tumour cells. The three tumour 
lines used in this study are the three genetic variants RBL5-Dd (Kb+Db+Dd), RMA (Kb+Db+Dd-) 
and RMA-S (with severely impaired MHC-I expression and perceived as MHC-I deficient by 
NK cells; as described in the materials section). Tumour ascites lines, as opposed to in vitro 
cultured tumours were used to avoid possible alterations in in vitro cultures that might affect 
rejection, and to accommodate the need for large quantities of cells needed for in vivo 
rejection studies. 
We used two different dyes: CFSE together with the cell tracker dye Violet (BMQC Cell 
tracker). This dye enters cells and forms impermeant products. It is also toxic to cells in 
higher concentrations. As we were planning to use it for the spleen target cells (measured 
over a longer time period but with non-dividing target cells) as well as the tumour target cells 
(measured over a shorter time but with dividing target cells), it needed to be titrated and 
tested separately for the different types of cells. 
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In the titration experiments, we labelled syngeneic B6 spleen cells (not rejected) with 
different concentrations of the Violet dye. The cells were analysed by flow cytometry and 
inoculated in mice. Several test concentrations (0.5, 1, 5, 10, 20µM) of Violet dye were used 
in separate groups and inoculated cells were followed in vivo over 4 days (the length of our 
longest rejection assay) through analysis of blood or spleen cells at the end of the assay 
(Figure 10). We found that the Violet dye had to be used at a high concentration. Also, it was 
not possible to use it in more than one concentration in the same cell mixture (like we did for 
CFSE) as it lost intensity in vivo, and even at a high concentration the fluorescence intensity 
was low at the end of the assay. The lowest concentration of Violet dye that allowed the 
labelled cells to be clearly discernible from negative cells was 10µM and cells labelled with 
this concentration were analysed also in a mixture with CFSEhi and CFSElo cells in order to 
confirm that all three cell populations could be clearly distinguished at the end of the assay 
(Figure 11). The same Violet concentration was found to work best also for tumour cell 
labelling (data not shown). 
4.3.2   Kinetics  of  spleen  and  tumour  cell  rejection  
For normal spleen cell targets, rejection was followed over four days (in blood) and finally 
after sacrifice (in spleens). The kinetics of the assay was analysed to identify a window where 
rejection could be appreciated without losing control cell populations significantly. As shown 
in Figures 11 and 12, sufficient resolution between cell populations and maximal rejection of 
all susceptible cell types were achieved on day 4. In the tumour challenge assay, rejection 
was more efficient and due to proliferation of target cells, fluorescence was lost more rapidly, 
at 36 hours the labelled populations could not be clearly detectable, rejection thus had to be 
measured at earlier time points (up to 24 hours) (Figure 13) and measured only in spleen. 
Blood analysis was not reliable due to low numbers of tumour cells in the blood (not shown). 
One concern we had regarding the three cell assay was that the addition of a third cell 
population might affect the kinetics or extent of rejection of the other target cells. This could 
be due to target cell competition or target cell interaction dynamics within the inoculate. To 
address this issue, we conducted experiments where we compared rejection of MHC-I– cells 
using the two-cell assay and the three-cell assay (Figure 14). We found that target cells were 
similarly rejected in both the two-cell and the three-cell assay. This observation was of 
significance as the initial experiments done in the DL6 study were two-cell assays and later, 
we used the three-cell assays to expand the study scope, and findings from both needed to be 
comparable. 
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Figure 10. Titration of Violet (BMQC) dye on spleen cells used as in vivo target cells. Spleen 
cells were labelled with different concentration of Violet dye, inoculated i.v. into syngeneic 
mice and analysed in the spleen after four days. Plots show flow cytometry analysis A. directly 
after labelling and, B after four days. The concentration chosen for further experiments 
(10µm) is indicated.    
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Figure 11. Monitoring survival of three different target cells inoculated in the same mouse. 
Spleen cells were labelled with two different concentrations of CFSE and Violet dye 
respectively, mixed 1:1:1 and inoculated i.v. into NK depleted mice to test resolution of the three 
populations at different time points. The labelled cell mixture was analysed at the time of 
inoculation, in the blood of inoculated mice on day two and in the spleen on day four after 
inoculation. 
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Figure 12. Kinetic analysis, missing self rejection of spleen target cells. Spleen cells from D8, B6 
and β2m-/- mice were labelled with two different concentrations of CFSE and Violet dye 
respectively, mixed 1:1:1 and inoculated i.v. into D8 and DL1 mice, untreated or NK cell depleted. 
The labelled cell mixture was analysed at the time of inoculation, in blood on day two and day 
four. Graphs show corrected cell ratios for β2m-/-/D8 (A) and B6/D8 (B). One representative 
experiment with means of two mice per group. 
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Figure legend appears on next page 
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Figure 13. Kinetic analysis, missing self rejection of tumour target cells. Representative FACS 
plots showing: A. inoculate of a 1:1:1 mix of RBL-5Dd (Violet), RMA (CFSE-lo) and RMA-
S (CFSE-hi), B. analysis in spleen of an inoculated B6 mouse at 16, 24 and 36 hours, C. Bar 
diagram showing the corrected ratio of target cells versus control cells: RMA-S/RBL5Dd (top) 
and RMA/RBL5Dd (bottom) at 16 and 24 hours. One experiment with two mice per group. 
Error bars, SD. 
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4.3.3   Calculation  of  results  
When injecting cells intravenously, there is sometimes variation between individual mice in 
the volume, i.e. the number of cells that get injected. The control cell population was used to 
correct for this. Thus, the final target-to-control ratios were corrected for the inoculated ratios 
to obtain the target cell survival ratio (for the formula, see materials and methods section). 
This method took into account internal controls for both inoculated and final readouts within 
Figure 14. Comparison of two cell assay and three cell assay with spleen target cells. Spleen 
cells from β2m-/-, B6 and D8 mice were labelled with two different concentrations of CFSE 
and Violet dye respectively, and either mixed β2m-/-+B6+D8 (black bars) or β2m-/-+D8 (grey 
bars) and inoculated i.v. into D8 and B6 mice, untreated or NK cell depleted, as well as DL1 
and β2m-/- mice. The labelled cell mixture was analysed at the time of inoculation as well as in 
blood on day one (top) and spleen on day four (bottom). Graphs show corrected cell ratios for 
β2m-/-/D8. One experiment with means of two mice per group. 
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each mouse. It did not, however, account for any changes in the control population that might 
have occurred in vivo due to a number of reasons, e.g. rejection.  
Another strategy for showing these data was also employed where survival of each cell type 
was measured as percent of total spleen cells, without relating it to any control population. 
This allowed for analysis without influence of a potential rejection of the control population. 
However, putative preferential homing of any cell type in a certain mouse strain, or variation 
in spleen size between individual mice may still confound this analysis.  
The data for spleen cell rejection is presented in both ways so that it can be analysed in 
different ways, accounting for different factors. Owing to the multiple variables involved, 
namely; various test-control cell combinations, several mouse strains with different MHC-I 
phenotypes, and possible involvement of other immune cell types especially in longer assays, 
this gives a fuller picture of the results.  
4.4   NK  CELLS  IN  DL6  MICE  ARE  TOLERANT  TO  CELLS  LACKING  Dd  BUT  
EXPRESSING  Kb  AND  Db      
With the set of typed mice and new or optimized assays described in the previous sections, 
we were in a position to test quantitative aspects of tolerance in the mosaic DL6 mice. It has 
been shown previously that such mice do not reject cells lacking Dd in vivo in assays 
measuring rejection of BM cells or outgrowth of subcutaneously inoculated tumour cells 
[92]. This indicated a complete NK cell tolerance to “allele specific missing self” in this 
setting of mixed MHC environment. However, neither of the assays used were quantitative, 
thus it was still possible that a low grade rejection of Dd negative cells would escape 
unnoticed.  In addition, the study did not address “true tolerance” to resting healthy cells in 
untreated normal mice – the BM rejection assay involved rapidly proliferating 
haematopoietic cells grafted to sub-lethally irradiated mice. To study how the DL6 mice 
respond to healthy spleen cells having a partial lack in MHC-I molecules in a more 
quantitative assay, Kb+Db+Dd- and Kb+Db+Dd+ (hereafter referred to as Dd- and Dd+ cells 
respectively) spleen cells were labelled with different fluorescent dyes and DL6 mice were 
challenged with these targets. In these experiments, also differentially labelled cells, 
completely lacking MHC I, were included according to the method described above, in order 
to study general missing self responsiveness. The results for such cells are discussed below.  
We reasoned along two hypotheses. 1) Mosaic mice would be completely tolerant towards 
Dd- target cells up to a certain frequency of host Dd+ cells, when the few host Dd- cells were 
not sufficient to render the relevant NK subsets hyporesponsive. Mice with frequencies of 
Dd+ cells above this threshold would efficiently eliminate Dd- spleen cells. 2) The tolerance 
would not be absolute in any of the mosaic mice, it would gradually change depending on the 
frequency of Dd+ cells. This should be possible to read out as a correlation between the 
frequency of Dd+ cells and a partial elimination of Dd- spleen cells.   
The results did not fit any of these two hypotheses. Control mice D8 and DL1 (Kb+Db+Dd+) 
rejected Dd- B6 spleen cells efficiently, displayed as a markedly reduced survival ratio. In 
contrast, there was no clear-cut rejection by any of the DL6 mice tested, irrespective of the 
frequency of Dd+ cells (ranging from 9 to 94%; Figure 15A). There was no frequency 
threshold above which the pattern changed in a convincing way, although we note that the  
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only DL6 mouse which could be formally classified as a “rejector” (arbitrarily defined as a 
survival ratio of B6/D8 cells > mean + 2 SD of DL1 mice) also had the highest frequency of 
Dd+ cells (94%; Figure 15A). Furthermore, there was no significant correlation between the 
frequency of Dd+ cells and the survival of Dd- spleen cells in a linear regression analysis 
(Figure 15B). The rejection in D8 and DL1mice was NK cell dependent as mice depleted of 
NK cells did not reject such cells. We conclude that tolerance to Dd- normal cells is robust in 
mosaic mice, even when the frequency of Dd+ cells is high. This indicates that NK cell 
education is induced or maintained through interactions with multiple cells, where even few 
cells deficient for an inhibitory MHC ligand will dominantly determine tolerance towards this 
phenotype. 
Figure 15. Relative survival of B6 vs. D8 spleen cells in DL6 mice with different frequencies of Dd+ 
cells. Fluorescence labelled β2m-/- (not shown), B6 (target) and D8 (control) cells were inoculated 
i.v. into mice of different strains that were untreated or treated with depleting anti-NK1.1 mAb. 
Results are displayed as a corrected ratio of target cells versus control cells. Survival of target cells 
was analysed in spleens four days after inoculation. A. The left part of the figure shows means of 
mice within each group and the right part of the figure shows all individual DL6 mice from the DL6 
group (shown as a mean value to the left) with frequency of Dd+ cells denoted on the x axis. DL6 
Ly5.1 mice are denoted by grey bars. The figure shows a compilation of 6 experiments with at least 
8 mice in each group, except 6 mice in DL1, 4 in DL1 NK depleted, 46 in DL6 and 19 in DL6 NK 
depleted group. Error bars denote SD. The naïve DL6 group was statistically compared with all 
other naïve groups and DL6 NK depleted group. Statistically significant differences are denoted: 
****, P < 0.0001. The black arrow indicates the rejection cut-off (0.469) calculated as mean+2SD of 
DL1 control. B. The figure shows B6/D8 ratio (y axis) in individual DL6 mice plotted against 
frequency of Dd+ cells (x axis). The figure shows the same data for individual DL6 mice as in A.  
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The pattern observed in one of the controls of these studies raised a concern about the use of 
relative survival ratios calculated against the D8 control target population.  In B6 mice, there 
was a high survival ratio, frequently above 1, suggesting that the control population in the 
assay (i.e. D8 cells) had decreased. Such a decrease would lead to a survival ratio above 1 for 
the test population, in this case, the syngeneic B6 cells. This to some extent was observed for 
NK cell depleted B6 mice as well, pointing out that an NK cell dependent and/or independent 
rejection of the D8 target population (Dd+) may have occurred. It should be noted that 
Ly49D+ NK cells in B6 mice are able to reject Dd expressing (D8) cells in bone marrow 
rejection assays in irradiated mice [233], also fully allogeneic BALB/c H-2d spleen cells have 
been shown to be rejected in an DAP12 dependent manner (indicating involvement of 
Ly49D) in B6 mice [117]. Other cytotoxic cells e.g. CD8+ T cells in the second line of 
defence, have slower time kinetics, and these cells may play a role during longer assays.  
To analyse if rejection of D8 cells could be the cause of the observed high survival ratio, not 
only in B6 mice but possibly also in DL6 mice (which could conceal a potential rejection of 
Dd- B6 cells), we also calculated the results as “percent remaining labelled B6 and D8 cells of 
the total spleen cells” rather than as a survival ratio (Figure 16A and 16B respectively; please 
see materials and methods as well as the section on refinement of in vivo rejection assay 
above for detailed presentation of these calculation methods). As expected, the percent 
remaining B6 cells was reduced in D8 and DL1 groups in an NK cell dependent manner, 
while B6 and DL6 mice did not show any such reduction (Figure 16A). In contrast, the 
survival of D8 spleen cells was clearly reduced in B6 mice with and without NK cell 
depletion, while the other mouse strains did not show any such reduction (Figure 16B). To 
test if CD8+ T cells could play a role, we depleted such cells in a control experiment (Figure 
17). There was a trend towards higher percent remaining D8 spleen cells and lower B6/D8 
ratios in B6 mice after CD8+ T cell as well as NK cell depletion, reflecting better survival of 
Dd+ D8 cells in these control groups, even if no statistically significant differences were 
observed. For DL6 no similar trend could be observed. In conclusion, B6 mice seem to reject 
D8 cells in a not yet fully characterized manner, possibly several cell types are involved. 
Importantly, the results showed that in DL6 mice, there was no rejection of D8 spleen cells, 
thus these cells could be used as a control population to calculate ratios which reflect survival 
of the test populations.  
Figure 16. Survival of B6 and D8 spleen cells in DL6 mice with different frequencies of Dd+ cells. 
Fluorescence labelled β2m-/- (not shown), B6 and D8 cells were inoculated i.v. into mice of different 
strains that were untreated or treated with depleting anti-NK1.1 mAb. Results are displayed as 
surviving B6 target cells (A) or D8 target cells (B) in percentage of total spleen cells. Survival of target 
cells was analysed in spleens four days after inoculation. The left part of the figure shows means of 
mice within each group and the right part of the figure shows individual DL6 mice (from the DL6 
group shown to the left) with frequency of Dd+ cells denoted on the x axis. DL6 Ly5.1 mice are 
denoted by grey bars. The figure is based on the same data as figure 15 and shows 5 experiments with 
at least 8 mice in each group, except 6 mice in DL1, 4 in DL1 NK depleted, 46 in DL6 and 19 in DL6 
NK depleted group. Error bars denote SD. The naïve DL6 group was compared with all other naïve 
groups and DL6 NK depleted group. Statistically significant differences are denoted: **, P < 0.01; 
****, P < 0.0001. 
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Figure 17. Analysis of the role of CD8+ T cells and NK cells for survival of B6 and D8 spleen cells 
in a four day rejection assay. Fluorescence labelled β2m-/- (not shown), B6 and D8 cells were 
inoculated i.v. into mice of different strains that were untreated or treated with depleting anti-CD8 or 
anti-NK1.1 mAb. Results are displayed as surviving D8 target cells (% of total spleen cells) (A) or 
B6/D8 survival ratio (B). Survival of target cells was analysed in spleens four days after inoculation. 
The figure shows one experiment with means of two mice in each group. Error bars denote SD. The 
naïve group in each mouse strain was compared with its respective CD8 and NK1.1 depleted groups.  
Statistically significant differences are denoted: *, P < 0.05; ***, P < 0.001. 
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4.5   DL6  MICE  SHOW  A  REDUCED  REJECTION  OF  Β2M-­/-­  SPLEEN  CELLS  
COMPARED  TO  D8  AND  DL1  MICE  
The results thus indicated that all mosaic DL6 mice develop a complete tolerance to normal 
Dd- cells. We speculated that this might be due to hyporesponsiveness in one or more NK cell 
subsets (as defined by Ly49r expression) which would be highly responsive and “missing self 
reactive” in mice with normal Dd expression. We reasoned that such a hyporesponsiveness in 
several NK subsets due to the presence of a conflicting MHC-I environment (Dd mosaic) 
should lead to reduced overall rejection capacity towards MHC-I deficient cells. We further 
speculated that such a reduced rejection capacity might be quantitatively influenced by the 
frequency of Dd- cells in the mice, since this frequency would particularly influence the subset 
which would be missing self-reactive in mice with normal Dd expression. We thus set out to 
test whether DL6 mice would show reduced capacity for general missing self rejection, again 
with two possible models in mind. 1) This reduced capacity would only occur in mice with 
frequencies of Dd+ cells below a certain threshold, 2) Increased number of Dd+ cells would 
correlate with gradually increased general missing self responsiveness across the span of 
frequencies of Dd+ vs. Dd- cells. 
We could indeed observe a consistent, overall reduction in general missing self rejection 
capacity in DL6 mice (Figures 18, 19). This was most obvious in the early phase after 
inoculation of target cells, but the reduced rejection was not simply a matter of delayed 
kinetics; it persisted and was still present on day 4 (Figure 18). There was considerable 
variability, with a profound reduction in some mice, and less in other mice. However, 
rejection was never completely abolished, as shown by the comparison with the rejection 
pattern in β2m-/- mice (Figure 19A). Although high and low responders could be found across 
the entire span of frequencies of Dd+ cells in the DL6 mice, a fair (r = -0.57) and highly 
significant inverse correlation between this frequency and survival of the β2m-/- target cells 
emerged in a linear regression analysis (Figure 19B). Furthermore, although we did not 
observe a clear-cut off threshold above which all DL6 mice responded as well as D8 and DL1 
mice, we note that the majority (5/8) mice with 79% or more Dd+ cells were within two 
standard deviations of the average β2m-/- /D8 survival ratio observed for DL1 mice, our 
arbitrary cut-off for a normal, fully efficient general missing self rejection (Figure 19A). We 
further note that many but not all DL6 Ly5.1 mice were in this category of arbitrarily defined 
“complete rejectors”.  Mice from this breeding were included in order to extend the number 
of mice with high frequencies of Dd+ cells, but it cannot be formally excluded that the Ly5.1 
mice differ in some other respect which influences the NK cell system.  
Considering the correlation between frequencies of Dd+ cells and the capacity for general 
missing self rejection of β2m-/- cells, we also performed a linear regression analysis to explore 
any possible correlation between the survival of β2m-/- and survival of B6 cells in the subset 
of experiments where both of these target cells had been included. As seen in Figure 20A, the 
data do not support such a correlation, despite the fact that the moderate inverse correlation (r 
value = -0.63) between frequency of Dd+ cells and survival of β2m-/- cells was seen also in this 
subset of experiments (Figure 20B), This is in line with the notion that tolerance to allele 
specific missing self (i.e. the Dd- phenotype of B6 cells) was complete regardless of the 
frequency of Dd+ cells in the DL6 mice.  
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Figure 18. Kinetics of rejection of β2m-/- spleen cells by D8 and DL6 mice. Fluorescence 
labelled β2m-/- (target) and D8 (control) cells were inoculated i.v. into mice of different strains 
that were untreated or treated with depleting anti-NK1.1 mAb. Results are displayed as a 
corrected ratio of target cells versus control cells. Survival of target cells was analysed in blood 
one to four days after inoculation. The figure shows two individual D8 control mice and five 
DL6 mice with frequency of Dd+ cells denoted in the legend. The figure shows mice from one 
representative experiment out of 9.  
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We conclude that in an environment of mixed MHC phenotypes, the frequency of cells with a 
“complete” MHC-I expression (in this case Kb+Db+Dd+) correlates with higher capacity for 
general missing self rejection by NK cells (as measured by rejection of cells with the Kb-Db-
Dd- phenotype). Phrased differently, it thus appears that the presence of cells representing 
allele-specific missing self (Kb+Db+Dd-) in the mixed MHC-I milieu, not only induces 
complete tolerance to allele specific missing self, but also “numbs” the overall responsiveness 
of the NK system as a whole. Overall, these findings are well in line with the predictions of 
the rheostat model for NK cell education [96] postulating that the MHC-I input received by 
inhibitory NK receptor gradually tunes the responsiveness of each NK cell. A more detailed 
discussion of this, as well as possible cellular mechanisms for this pattern will be presented 
below, taking into account also the results obtained from studies of tumour cell rejection.  
Figure 19. Relative survival of β2m-/- vs D8 spleen cells in DL6 mice with different frequencies 
of Dd+ cells. Fluorescence labelled β2m-/- (test) and D8 (control) cells (in some cases also in mix 
with B6 cells; not shown) were inoculated i.v. into mice of different strains that were untreated 
or treated with depleting anti-NK1.1 mAb. Results are displayed as a corrected ratio of target 
cells versus control cells. Survival of target cells was analysed in spleens four days after 
inoculation. A. The left part of the figure shows means of mice within each group and the right 
part of the figure shows all individual DL6 mice from the DL6 group (shown as a mean value to 
the left) with frequency of Dd+ cells denoted on the x axis. DL6 Ly5.1 mice are denoted by grey 
bars. The figure shows 9 experiments with at least 8 mice in each group, except 6 mice in DL1, 4 
in DL1 NK depleted, 61 in DL6 and 19 in DL6 NK depleted group. Error bars denote SD. The 
naïve DL6 group was compared with all other naïve groups and DL6 NK depleted group. 
Statistically significant differences are denoted: **, P < 0.01; ****, P < 0.0001. The black arrow 
indicates the rejection cut-off (0.025) calculated as mean+2SD of DL1 control. B. The figure 
shows β2m-/-/D8 ratio (y axis) in individual DL6 mice plotted against frequency of Dd+ cells (x 
axis). The figure is based on the same data for individual DL6 mice as in A. 
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Figure 20. Survival of β2m-­‐/-­‐ spleen cells correlated to survival of B6 spleen cells (A) or 
frequency of Dd+ cells (B) in DL6 mice. Fluorescence labelled β2m-/- (test), B6 (test) and D8 
(control) cells were inoculated i.v. into mice of different strains that were untreated or treated 
with depleting anti-NK1.1 mAb. Results are displayed as a corrected ratio of target cells 
versus control cells. Survival of target cells was analysed in spleens four days after 
inoculation. A. The figure shows B6/D8 ratio (y axis) in individual DL6 mice plotted against 
β2m-/-/D8 ratio (x axis). B. The figure shows β2m-/-/D8 ratio (y axis) in individual DL6 mice 
plotted against frequency of Dd+ cells (x axis).  The graphs are based on 46 DL6 mice, which 
represent a subset of the data in figure 19.  
 66 
4.6   IMPACT  OF  MOSAIC  MHC-­I  EXPRESSION  IN  THE  NON-­
HAEMATOPOIETIC  ENVIRONMENT,  ON  REJECTION  OF  SPLEEN  CELLS  
REPRESENTING  MISSING  SELF  
So far, the results indicated that NK cells developed robust tolerance to Dd- cells even if there 
were less than 15% of such cells in the host. This led to the question whether tolerance could 
develop even in mice where all cells in the haematopoietic system expressed Dd and where 
the mosaic expression of this molecule was restricted to the non-haematopoietic tissues.  
We tested this by transplanting D8 bone marrow to DL6 mice with various proportions of Dd 
expressing cells, and then testing for rejection via missing self recognition. These D8 ® DL6 
chimaeras were thus tested for rejection of MHC-I sufficient B6 spleen cells lacking 
expression of Dd specifically, as well as MHC-I deficient β2m-/- spleen cells. While the D8 ® 
D8 chimaeras rejected B6 cells, the D8 ® DL6 chimaeras showed strict tolerance, 
irrespective of the frequencies of Dd expressing cells in the recipient DL6 mice (Figure 21A). 
The same pattern was seen in the D8 ® B6 chimaeras, where the recipients did not have a 
mosaic environment or any Dd expression at all. In contrast, there was an efficient rejection of 
the β2m-/- spleen cells by the D8 ® DL6 chimaeras, comparable to that seen in D8 ® D8 
chimaeras (Figure 21B). 
From this experiment, we conclude that it is sufficient to have a fraction of non-
haematopoietic cells lacking a specific MHC-I molecule, to induce tolerance for NK cell 
mediated allele specific missing-self responsiveness, even if all the cells in the 
haematopoietic system express this MHC-I molecule. However, the general responsiveness to 
cells completely lacking MHC-I molecules was not significantly reduced in this situation, 
suggesting differences in the regulation of rejection triggered by allele specific missing self 
versus the one triggered by complete missing self. It should be noted that this observation 
differs from what was observed in DL6 mice above (Figure 19A), where all mice showed a 
generally weakened (although not totally impaired) general rejection capacity towards MHC-
I negative normal cells. One possible explanation is that the capacity to develop full 
responsiveness for general missing self rejection is more influenced by educating cells in the 
haematopoietic compartment, which represented a mixed Dd+/Dd- environment in the DL6, 
but not in the D8 ® DL6 chimaeras. It should be noted that the difference may be 
quantitative rather than qualitative. The Dd- cells in the nonhaematopoietic environment may 
be sufficient to educate for impaired responsiveness to the extent that the critical NK subsets 
do not reject Dd- spleen cells, although in the absence of Dd- cells in the haematopoietic 
system, this impairment is not sufficiently profound to allow detection of generally reduced 
responsiveness against MHC-I deficient cells. 
Overall, these results place emphasis on the Dd- cells in DL6 mice, once more, as the cells 
tutoring the lessons in education, but in this case focusing on non-haematopoietic cells. They 
also add to the notion of a very robust process for tolerance towards normal cells representing 
allele specific missing self. 
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Figure 21. Analysis of β2m-/- and B6 spleen cell rejection in D8 ® DL6 bone marrow 
chimaeras. A mix of fluorescence labelled β2m-/- (test), B6 (test) and D8 (control) cells was 
inoculated i.v. into bone marrow chimaeras and naïve controls that were untreated or treated 
with depleting anti-NK1.1 mAb. The D8 ® DL6 chimaeras were divided in two groups, 
where the DL6 host carried <50% or >60% Dd+ cells in peripheral blood before BM 
transplantation, as indicated on the x axis. Results are displayed as a corrected ratio of target 
cells versus control cells. Survival of target cells was analysed in spleens four days after 
inoculation. A. shows B6/D8 survival ratio and B. shows β2m-/-/D8 survival ratio.  The 
figure shows 2 experiments with at least 4 mice in each control group and 12 mice in each 
chimaera group without NK1.1 depletion. Error bars denote SD. Statistical analysis was 
done in comparing A. D8®B6 as well as the two D8®DL6 chimaera groups with naïve 
DL6 mice and with their respective NK1.1 depleted control groups (n.s.), also no significant 
difference between D8®DL6 chimaera groups; B. D8®B6 as well as the two D8®DL6 
chimaera groups compared to D8®D8 (n.s.), also no significant difference between 
D8®DL6 chimaera groups. 
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4.7   MISSING  SELF  REJECTION  OF  TUMOUR  CELLS  IN  DL6  MICE    
We also studied tumour rejection in DL6 mice, with the methods developed and described 
above. Tumour cells often have more ligands for activating receptors on NK cells, resulting 
in higher susceptibility to killing and altered threshold for missing self rejection as already 
discussed above. We reasoned that this feature of tumour cells might result in a more 
sensitive system to detect quantitative alterations in tolerance induction in the DL6 mice. We 
thus decided to test the hypothesis that breaking of tolerance towards ‘‘allele specific missing 
self’’ would be revealed in DL6 mice with lower numbers of Dd- cells when tumour targets of 
the Dd- phenotype were used, even if the mice remained tolerant to normal cells of the Dd- 
phenotype as shown above. The three tumour lines used in this assay were the three genetic 
variants RBL5-Dd (Kb+Db+Dd+, referred to as Dd+), RMA (Kb+Db+Dd-, referred to as Dd-), and 
RMA-S with severely impaired MHC-I expression and perceived as MHC-I deficient by NK 
cells [78], referred to as MHC-I-.  
The tumour cell based assays showed rather large intra-experimental variations between 
individual mice, even in control groups with identical MHC-I expression, when calculated as 
percentage of surviving target cells per spleen cell. There could be several explanations for 
this, e.g. differential homing patterns of tumour as opposed to normal cells. Furthermore, 
there were no indications that B6 mice rejected the tumour cells used as internal controls: 
RBL-5Dd (data not shown). Since the important comparison is the one between the different 
tumour cells, the data are therefore shown only as survival ratios in relation to RBL-5Dd. This 
ratio showed only a small intra-experimental variability between individual mice when 
tumour cells were used. Again, we considered two possibilities: 1) Breaking of tolerance 
towards Dd- RMA cells above a certain frequency of Dd+ cells in the DL6 mice 2) Increased 
number of Dd+ cells would correlate with gradually increased allele specific missing self 
responsiveness against RMA cells, across the span of frequencies of Dd+ vs Dd- cells.  
The observed results were consistent with the latter model. While RMA cells were rejected in 
D8 and DL1 mice, there was considerable variability observed among DL6 mice, with no 
rejection in many mice and almost as efficient rejection as in D8 or DL1 by some mice 
(Figure 22A).  
 Although “high” and “low” responders could be found across the entire span of frequencies 
of Dd+ cells in the DL6 mice, a weak but highly significant inverse correlation (r = -0.46) 
between this frequency and survival of the RMA target cells emerged in a linear regression 
analysis (Figure 22B). In some experiments, we analysed the survival in low responders after 
two days until the tumour cells were no longer detectable in spleen, and we could not observe 
any delayed rejection kicking in (data not shown).  
Using an arbitrary level of the average RMA/RBL-5Dd survival ratio + two standard 
deviations in positive DL1 control mice as cut-off for “rejection” ratio, we found “rejectors” 
across the span of frequencies of Dd+ vs Dd- cells. However, all mice with ≥83% Dd+ were 
qualified as “rejectors”, suggesting that tolerance to Dd- tumour cells is broken at this 
threshold of just below 20% of Dd- cells. Again, we cautiously noted that all the mice with 
≥83% Dd+ cells were from the DL6 Ly5.1 breeding line. 
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This led us to the expectation that DL6 mice would display a reduced capacity in general 
missing self reactivity also against MHC-I deficient tumour cells, corresponding to what we 
had seen with normal spleen cell targets. However, when we monitored the rejection of 
MHC-I deficient RMA-S tumour cells, DL6 mice rejected these cells very efficiently, 
comparable to D8 and DL1 mice. We studied this over a time line of 2 days and found that 
RMA-S rejection in DL6 mice began within 6-8 hours and was completed within 16- 24 
hours (Figure 22C and D).  
Interestingly, this pattern was different from the one we had observed with the healthy 
counterpart of RMA-S, i.e. MHC-I deficient spleen cells, which showed a clearly reduced 
missing self rejection in DL6 mice. This is reminiscent of what we observed in our studies of 
retuning by inhibitory receptor blockade as discussed above [222]. It thus appears that a 
mixed MHC-I expression in the host environment can differentially regulate reactivity to 
normal and tumour cells, similar to inhibitory receptor blockade or adoptive transfer of NK 
cells. To explain all of our observations in the DL6 mice, we propose that a higher expression 
of NK cell activating ligands on tumour cells brings them over a threshold where the general 
missing self hyporesponsiveness of DL6 NK cells cannot be detected in the assay for 
rejection of RMA-S tumour cells. This hyporesponsiveness is however sufficient to partly 
reduce the rejection capacity against MHC I deficient normal cells as well as RMA tumour 
cells (lacking one MHC I allele), and to completely abrogate rejection capacity against 
normal B6 spleen cells (lacking one MHC I allele).  
 
Figure 22. Relative survival of RMA or RMA-S versus RBL5Dd tumour cells in short term rejection 
assays in DL6 mice. A-D. Fluorescence labelled RMA (test) and RBL5Dd (control) cells (A-B) or 
RMA-S (test) and RBL5Dd (control) cells (C-D) were inoculated i.v. into mice of different strains 
that were untreated or treated with depleting anti-NK1.1 mAb. Results are displayed as a corrected 
ratio of target cells versus control cells. A. Survival of RMA tumour cells in 18-24 hour assays. 
The figure shows a compilation of three experiments with a total of at least 6 mice in each control 
group, 51 DL6 mice and 21 DL6 NK depleted mice. The black arrow indicates the rejection cut-
off (0.574) calculated as mean+2SD of DL1 control. B. The figure shows RMA/RBL-5Dd (y axis) 
in individual DL6 mice plotted against frequency of Dd+ cells (x axis) and is based on the same 
data as in (A). C. Survival of RMA-S tumour cells in an 8 hour short term rejection assay. One 
experiment with 2 mice each control group, 7 DL6 and 4 DL6 NK depleted mice. D. Survival of 
RMA-S tumour cells in a 24 hour short term rejection assay. One experiment with 2 mice each 
control group, 13 DL6 and 7 DL6 NK depleted mice. A, C, D. The left part of the figure shows 
means of mice within each group and the right part of the figure shows individual DL6 mice (from 
the DL6 group shown to the left) with frequency of Dd+ cells denoted on the x axis. DL6 Ly5.1 
mice are denoted by grey bars. Error bars, SD. The naïve DL6 group was compared with all other 
naïve groups and DL6 NK depleted group. Statistically significant differences are denoted: ****, P 
< 0.0001. 
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4.8   IMPACT  OF  MOSAIC  MHC-­I  EXPRESSION  IN  THE  NON-­
HAEMATOPOIETIC  ENVIRONMENT  ON  REJECTION  OF  TUMOUR  CELLS  
REPRESENTING  MISSING  SELF  
The interpretation suggested in the end of the previous section led us to revisit the model 
where mosaic MHC-I expression was manifested exclusively in the non-haematopoietic 
compartment, i.e. the D8 ® DL6 chimaera. As noted above, such chimaeras were completely 
tolerant towards the B6 spleen cells, representing allele specific missing self, although their 
general missing self responsiveness towards the β2m-/- cells was fully efficient. If the same 
hierarchy applied in that situation as in the untreated DL6 mice, we would expect to detect 
rejection of RMA tumour cells (lacking only one allele of the cells in the haematopoietic 
compartment) in such mice, although it might be weakened compared to mice without mosaic 
MHC expression.   
Our further experimental observations confirmed this (Figure 23). The D8 ® D8 chimaeras 
efficiently rejected RMA cells. The two groups of D8 ® DL6 chimaera showed significantly 
reduced rejection compared to these positive controls, however both of the groups (with < 
50% and >60% Dd+ cells in blood before BM transplantation respectively) showed significant 
rejection compared to B6 ® B6 mice. One may also note that the D8 ® DL6 mice with 
>60% Dd+ cells rejected RMA cells more efficiently than the mice with <50% Dd+ cells (P < 
0.05). This suggests that the degree of mosaic expression in the non-haematopoietic tissues 
quantitatively influences the capacity for allele specific missing self rejection of tumour cells. 
From this experiment, we conclude that it is not sufficient with a fraction of non-
haematopoietic cells lacking a specific MHC-I molecule, to induce tolerance to NK cell 
mediated missing-self responsiveness against tumour cells lacking the same MHC-I 
molecule. This is in contrast to the responsiveness against normal cells representing allele 
specific missing self, where the corresponding situation led to complete tolerance, as 
discussed above (Figure 21A).  
The situation with heterogenous MHC expression among non-haematopoietic cells 
exclusively is of course not directly relevant to any clinical situation arising in an 
immunotherapy protocol. However, the results are of importance from the perspective of 
basic understanding of NK cell education, as they support a general concept already emerging 
from the previous data presented in this thesis. The essential notion is that the outcome of 
interfering with the education process via perturbed sensing of MHC I varies depending on 
the cells used for the readout. Tumour cells can remain sensitive to the NK system under 
conditions where there is complete tolerance to normal cells with the corresponding missing 
self phenotype. There is at least one situation where this consequence of heterogenous MHC 
expression can be exploited in clinical immunotherapy: haematopoietic chimaerism occurring 
after bone marrow/stem cell transplantation or adoptive transfer.  We therefore decided to set 
up an experimental system to assess the impact of mixed chimaerism in the haematopoietic 
compartment exclusively (with homogenous MHC expression in non-haematopoietic tissues) 
after bone marrow transplantation in mice.    
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4.9   STUDIES  ON  TUMOUR  CELL  REJECTION  IN  MIXED  BONE  MARROW  
CHIMAERAS  
The chimaera approach was also motivated from another point of view: the DL6 mice 
represented a limitation in the sense that the majority of them had a frequency of Dd+ cells 
around 30-70%, while mice with extreme frequencies of Dd+ cells were rare, even when 
Ly5.1 DL6 mice were used. In bone marrow chimaeras this should be possible to control, at 
least in theory. In order to study NK cell education in mice with very few Dd- cells we thus 
generated mixed bone marrow chimaeras where Dd+ and Dd- bone marrow from D8 and B6 
mice respectively was mixed in different predetermined percentages and transplanted into D8 
hosts. This allowed us to assess not only the quantitative influence of the number of Dd- cells 
on missing self tolerance, but also to test the influence of Dd- cells when this phenotype was 
present exclusively in haematopoietic cells. All the D8 recipient mice in this chimaeric model 
expressed Dd in all of the non-haematopoietic cells. 
When constructing these chimaeras, it was essential to prevent that Dd+ NK cells (from the 
Dd+ recipient mice as well from the Dd+ donor mice) rejected haematopoietic cells from the 
Figure 23. Analysis of RMA tumour cell rejection in D8 ® DL6 bone marrow chimaeras. 
A mix of fluorescence labelled RMA (test) and RBL5-Dd (control) cells was inoculated 
i.v. into bone marrow chimaeras and naïve controls that were untreated or treated with 
depleting anti-NK1.1 mAb. The D8 ® DL6 chimaeras were divided in two groups, where 
the DL6 host carried <50% or >60% Dd+ cells in peripheral blood before BM 
transplantation, as indicated on the x axis. Results are displayed as a ratio of target cells 
versus control cells. Survival of target cells was analysed in spleens 20 hours after 
inoculation. The figure shows one experiment with 2 mice in each control group, and 4 
mice in each chimaera group without NK1.1 depletion. Error bars denote SD. D8®B6 as 
well as the two D8®DL6 chimaera groups were compared to B6®B6 group, and 
D8®DL6 chimaera groups were compared with each other. Statistically significant 
differences are denoted: *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. 
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Dd- donor during reconstitution based on missing self. We tested several protocols for this NK 
cell depletion in pilot experiments. The bone marrow reconstitution was followed over time 
and the stability of the chimaeras was assessed by flow cytometry in blood cells after the 
initial lymphopenic period of about 10 days (Figures 24-26). We always observed an initial 
increase of the Dd+ population compared to the administered ratio in the input mixture of 
marrows. However, after ten days, the chimaerism usually stabilized, at least in experiments 
where donor as well as recipients had been NK cell depleted (Figures 24 and 25).  
Interestingly, when donors but not recipients were NK cell depleted, we did not achieve 
stable chimaerism. The proportion of Dd+ cells continued to increase throughout the life span 
of the mice (Figure 25). Altogether, the protocols allowed us to study chimaeras with a 
completely Dd+ non-haematopoietic compartment and high frequencies of Dd+ cells in the 
haematopoietic compartment, in a range extending beyond that offered by DL6 mice. In 
addition, we could compare the outcome of different experiments with 95% Dd+/ 5% Dd- 
mixed chimaerism, but where the mice appeared to be in a stable “tolerant” state in one case, 
and in an unstable “non-tolerant” state in the other. 
When the stable mixed bone marrow chimaeras constructed with NK cell depletion of donor 
as well as recipient mice were challenged with the mixture of tumour cells, we observed a 
clear rejection of Dd- RMA cells representing allele specific missing self in the mice that had 
received 100% Dd expressing D8 marrow cells (Figures 24, 25). This rejection was markedly 
weakened already in mice containing as little as 4-8% of Dd- negative cells in the 
haematopoietic system after stabilization of chimaerism (Figures 24, 25). However, the 
rejection capacity was not completely abrogated, as noted when compared to B6®B6 
chimaeras or normal B6 mice with no Dd- cells in the haematopoietic system. We also 
observed a significantly stronger rejection in chimaeras with 95% Dd+ (range: 94-98%) cells, 
than chimaeras with 61% Dd+ (range: 57-66%) cells in one experiment (Figure 25). The 
results are well in line with previous results where outgrowth of subcutaneous tumours was 
studied in the same type of bone marrow chimaeras [212]. In this study, the capacity to reject 
RMA tumours of mixed D8+B6 ®D8 chimaeras containing less than 20% Dd- cells, was 
clearly reduced compared to D8®D8 chimaeras (tumour outgrowth in 17/24 and 0/13 mice, 
respectively). However, the former were still more resistant than B6 mice (outgrowth in 
11/11 mice).  
A different picture emerged in unstable chimaeras where only donors had been depleted of 
NK cells. All the mixed D8/B6 ® D8 chimaeras (which had now developed to contain 94-
95% Dd+ cells, (range: 90-96%) showed strong rejection of RMA cells, comparable to that 
seen in D8 ® D8 chimaeras (Figure 26). 
From the mice developing unstable chimaerism, we conclude that the parallel reconstitution 
of Dd+ and Dd- cells in the same host (Dd+) environment does not always lead to tolerance 
towards allele specific missing self. Similar results have been published with mixed B6 wild 
type and β2m-/- bone marrow chimaeras. These mice gradually developed towards higher 
frequencies of B6 vs. β2m-/- cells, a process which was accelerated if the NK cells were 
activated, e.g. by murine cytomegalovirus infection [39]. In the future, it would be of interest 
to explore exactly why the system sets off in this “non-tolerance” direction in certain 
situations, since this could be harnessed for anti-tumour therapeutic effects. Here, this lack of  
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Figure 24. Analysis of RMA tumour cell rejection in stable mixed bone marrow chimaeras. 
A. Mixed bone marrow chimaeras were assessed for chimaerism at multiple time points. 
Mix D8/B6® D8 chimaeras were divided in three groups based on inoculation ratios, mean 
final D8/B6 ratio in peripheral blood is indicated for each group on the x axis. B. after 11 
weeks they were either NK depleted or left untreated and inoculated i.v. with a mix of 
fluorescence labelled RMA (test) and RBL5Dd (control) cells. Survival of target cells was 
analysed in spleens 18 hours after inoculation. Results are displayed as a ratio of target cells 
versus control cells. The figure shows one experiment with 2 mice in each NK depleted 
control group, and 4-6 mice in each chimaera group without NK1.1 depletion. Error bars, 
SD. The Mix D8/B6® D8 groups were compared to B6®B6 group as well as among each 
other. Statistically significant differences are denoted: *, P < 0.05; **, P < 0.01. 
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Figure 25. Analysis of RMA tumour cell rejection in stable mixed bone marrow chimaeras. A. 
Mixed bone marrow chimaeras were assessed for chimaerism at multiple time points. Mix 
D8/B6® D8 chimaeras were divided in two groups based on inoculation ratios, mean final 
D8/B6 ratio in peripheral blood is indicated for each group on the x axis. B. after 10 weeks 
they were inoculated i.v. with a mix of fluorescence labelled RMA (test) and RBL5Dd 
(control) cells. Survival of target cells was analysed in spleens 20 hours after inoculation. 
Results are displayed as a ratio of target cells versus control cells. The figure shows one 
experiment with 2 mice in each naïve group and 6 mice in each chimaera group. Error bars, 
SD. The Mix D8/B6® D8 groups were compared to B6®B6 group as well with each other 
Statistically significant differences are denoted: *, P < 0.05; **, P < 0.01; ***, P < 0.001. 
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Figure 26. Analysis of RMA tumour cell rejection in unstable mixed bone marrow chimaeras. 
A. Mixed bone marrow chimaeras were assessed for chimaerism at multiple time points. Mix 
D8/B6® D8 chimaeras were divided in two groups based on inoculation ratios, mean final 
D8/B6 ratio in peripheral blood is indicated for each group on the x axis. B. after 9 weeks they 
were either NK depleted or left untreated and inoculated i.v. with a mix of fluorescence 
labelled RMA (test) and RBL5Dd (control) cells. Survival of target cells was analysed in 
spleens 20 hours after inoculation. Results are displayed as a ratio of target cells versus control 
cells. The figure shows one experiment with 2 mice in each NK depleted control group, and 4 
mice in each chimaera group without NK1.1 depletion. Error bars, SD. B6®D8 as well as the 
two Mix D8/B6® D8 chimaeras groups were compared to B6®B6 group, and Mix D8/B6® 
D8 chimaera groups were compared with each other. Statistically significant differences are 
denoted: *, P < 0.05; **, P < 0.01; ****, P < 0.0001. 
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tolerance occurred when we avoided NK cell depletion of the host, leading to the speculation 
that NK cells themselves are critically involved as MHC educating cells. However, there are 
also other possible interpretations for this observation. 
From the experiments with stable mixed bone marrow chimaeras, we conclude that a low 
number (5%) of Dd- cells in the haematopoietic system reduces capacity for allele specific 
missing self rejection of tumour cells, but is not sufficient to induce complete NK cell 
tolerance to Dd- tumour cells. Considering that these mice showed stable chimaerism where 
the proportion of normal Dd- white blood cells did not gradually decrease with time, and 
therefore apparently were not rejected, these results again suggest that the quantitative 
regulation of NK cell tolerance differs between normal and tumour cells. In other words, it is 
possible to preserve some missing self reactivity to tumours even if there is complete 
tolerance to normal cells lacking a specific allele in a mixed MHC-I environment. Further 
understanding and exploration of this phenomenon may be useful in clinical settings, e.g. in 
haematopoietic transplantation and adoptive transfer of allogeneic (including haploidentical) 
NK cells. It should also be noted that strong general missing self responsiveness against 
MHC-I deficient RMA-S cells was seen in mixed bone marrow chimaeras (data not shown) 
representing a wide range of frequencies of Dd- negative cells. This emphasizes that NK cell 
anti-tumour reactivity against MHC-I deficient tumour cells can be sustained under chimaeric 
conditions. 
Regardless of the mechanisms behind unstable chimaeras and lack of tolerance, our 
observations in this experiment may indirectly support the validity of our read out assay 
based on elimination of intravenously inoculated target cells. When the mice apparently were 
continuously eliminating more and more of their own normal haematopoietic Dd- cells, our 
assay revealed strong rejection of tumour cells of the same allele specific missing self 
phenotype. However, it should be noted that we have no formal evidence that the unstable 
chimaerism was caused by NK cell mediated rejection. 
4.10   CONCLUDING  REMARKS  AND  FUTURE  PERSPECTIVES  
In order to summarize the results of the studies in this thesis, the specific aims will first be 
revisited below, with a brief note on the key results and conclusions for each one of them. 
This will be followed by discussion and presentation of a theoretical model integrating the 
key results from different experimental systems in the thesis. Testable predictions for single 
cell analysis of NK cells are derived from this model, as well as some of its implications for 
immunotherapy against tumours. 
Revisiting the specific aims: 
•   To analyse the kinetics of the effects of perturbed MHC-I sensing via NK cell 
inhibitory receptor blockade on missing-self reactivity. 
 
When MHC-I sensing by NK cells in B6 mice was perturbed by treatment with 
antibodies against inhibitory Ly49I/C receptors, it led to impairment of “general 
missing self reactivity” towards MHC-I deficient spleen cells, despite increased 
killing of MHC-I expressing RMA tumour cells. Both changes occurred early (16-24 
hours) after inhibitory receptor blockade, and it was not possible to separate them in 
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kinetic studies. Efficient killing of MHC-I defective RMA-S tumour cells as well as 
tolerance towards normal MHC-I expressing spleen cells were preserved (Section 4.1, 
Figures 4 and 5). The interpretation was that the inhibitory receptor blockade 
modulates two processes in parallel: the (re)tuning/education of NK cells (reduced 
responsiveness) and the effector-target interaction (increased killing).  
 
•   To further characterize and develop a previously described transgenic mouse model 
(DL6) encompassing mosaic expression of an MHC-I gene (Dd) [92], and in 
particular, to identify mice with high frequencies (>85%) of Dd expressing cells. 
 
The DL6 mosaic model was extended by studies of mice where the Dd transgene was 
present in homozygous form, and also by intercrosses to other strains. More than 
1300 individual mice from different breedings were typed. In previous studies of Dd 
transgene heterozygous mice, the frequency of Dd+ cells ranged between 10% and 
80%, and this was not affected to a great extent in Dd transgene homozygotes. 
However, there was a skewed distribution towards higher frequencies of Dd+ cells in 
DL6 Ly5.1 congenic mice, obtained by crossing DL6 to B6 Ly5.1 mice and 
subsequent intercrossing of F1 mice. These mice displayed frequencies of Dd+ cells 
ranging from 30% to 97% (Section 4.2, Figures 6,7 and 8). 
•   To develop refined in vivo assays for NK cell mediated rejection, to allow monitoring 
of three target cells simultaneously. 
 
It was possible to develop such assays based on staining of target cells with Violet 
BMQC dye and two different concentrations of CFSE dye, allowing the tracking of 
three types of spleen or tumour cells in vivo. Following kinetic analysis, we optimized 
the assay times to 18-24 hours for the tumour cell challenge, and to four days for the 
spleen cell challenge assay (Section 4.3, Figures 11, 12, 13 and 14). 
 
•   To determine a quantitative threshold for NK cell tolerance to “allele specific missing 
self”, in terms of the minimal frequency of ligand deficient cells required to induce 
tolerance in hosts with mosaic MHC-I expression. 
 
It was impossible to determine such a quantitative threshold for NK cell tolerance. All 
mosaic DL6 mice were completely tolerant towards normal Dd- spleen cells (“allele 
specific” missing self), even if they had a relatively high proportion of Dd+ vs. Dd- 
cells (Section 4.4, Figures 15, 16 and 17).  
  
•   To determine whether NK cell responsiveness against “general” missing self is 
influenced quantitatively by the proportion of cells with and without a given MHC-I 
ligand in mice with mosaic MHC-I expression. 
The results provided support for this hypothesis. There were varying degrees of 
impaired reactivity in the mosaic mice upon challenge with MHC-I defective spleen 
cells (“general” missing self), with a moderate inverse correlation between the 
number of host Dd+ cells and the survival of these target cells. In particular, there was 
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an efficient rejection in the majority of mice with ≥79% Dd+ cells (Section 4.5, 
Figures 18, 19 and 20). 
•   To determine whether mosaic MHC-I expression exclusively in the non-
haematopoietic host environment is sufficient to influence NK cell tolerance to “allele 
specific” missing self and “general” missing self responsiveness. 
 
The results provided support for this hypothesis in the case of normal cells 
representing “allele specific missing self”. In chimaera studies where Dd+ bone 
marrow was used to reconstitute mosaic DL6 mice, there was complete tolerance 
towards normal Dd- spleen cells, indicating that a fraction of ligand deficient non-
haematopoietic cells is sufficient to induce tolerance to normal cells of this 
phenotype. However, the general responsiveness to cells completely lacking MHC-I 
molecules was not significantly reduced in this situation, suggesting differences in the 
regulation of rejection triggered by “allele specific” missing self versus the one 
triggered by “general” missing self (Section 4.6, Figure 21; Section 4.8, Figure 23). 
 
•   To establish a model for generation of mixed (Dd- vs. Dd+) bone marrow chimaeras 
with high frequencies (>85%) of Dd+ cells, and with NK cell function maintained. 
 
It was possible to construct mice with stable mixed chimaerism of Dd+ and Dd- 
haematopoietic cells in a Dd+ host environment, using a protocol based on NK cell 
depletion of D8 (Dd+) and B6 (Dd-) bone marrow donors as well as of irradiated bone 
marrow D8 recipients (Section 4.9, Figures, 24, 24 and 26). Long term stability of 
chimaerism was observed even when the proportion of Dd+ vs. Dd- cells was in the 
range of 95% vs. 5% (Section 4.9, Figures 24 and 25). 
 
•   To determine whether mosaic/chimaeric MHC expression has a differential influence 
on reactivity towards normal vs. tumour cells, with respect to allele specific as well as 
general missing-self rejection. 
 
The results from three different models supported the hypothesis on such a 
differential influence. In DL6 mice, tolerance towards Dd- RMA tumour cells 
representing “allele specific” missing self was not complete, in contrast to the pattern 
observed for Dd- normal cells described above. Partial rejection was observed in many 
mice. There was a weak inverse correlation between the frequency of Dd+ cells and 
the survival of these target cells; in particular, there was a fair degree of rejection in 
all mice with ≥83% Dd+ cells. There was no influence of the frequency of Dd+ cells 
when rejection was assessed with MHC-I deficient RMA-S lymphoma cells; all DL6 
mice rejected these cells efficiently (Section 4.7, Figure 22). 
 
In the chimaera studies where Dd+ bone marrow was used to reconstitute mosaic DL6 
mice (i.e. full expression of Dd in haematopoietic cells, but mosaic expression in non- 
haematopoietic tissues) there was significant (but reduced) capacity for “allele 
specific missing self rejection” of Dd- RMA tumour cells (Section 4.8, Figure 23). 
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This is in contrast to the pattern of complete tolerance observed towards normal Dd- 
spleen cells in such chimaera, as described above. 
 
In mixed bone marrow chimaeras (Dd+/Dd- ® Dd+), there was a significant (but 
reduced) rejection of Dd- RMA tumour cells representing “allele specific” missing 
self. This occurred despite stable chimaerism and apparent tolerance towards normal 
Dd- cells.  
 
The results summarized above were based on two very different approaches to perturb MHC-
I self sensing (heterogeneic MHC-I environment vs. inhibitory receptor blockade), and 
several different experimental systems. Nevertheless, certain patterns may be discerned and it 
is possible to discuss many of the results within the same conceptual framework. Table 3 
gives a schematic overview of key results that form the basis of such a discussion.  
Complete tolerance was observed towards normal B6 target cells, in both approaches for 
perturbed MHC-I sensing (Table 3). This lack of reactivity was maintained in the case of 
inhibitory receptor blockade, where the control B6 mice were tolerant from the beginning. It 
was induced in the case of the mosaic DL6 mice, the main experimental model used in the 
thesis, where the control DL1 or D8 mice rejected B6 targets. In both experimental models, 
b2m-/- targets were rejected by NK cells, albeit at reduced levels due to the perturbed MHC-I 
sensing. Interestingly, this reduction showed a moderate but significant correlation with the 
frequency of Dd+ cells in the DL6 model. This frequency dependent, quantitative educational 
effect also emerged when the MHC-I expressing tumour target cells were used in the DL6 
model; there was no complete tolerance towards the tumour cells in the DL6 mice (Table 3). 
The same trend was observed also in the mixed B6/D8 ® D8 chimaeras as well as in the D8 
to DL6 chimaeras (not shown in the table). On the other hand, the MHC-I deficient tumour 
target cells were rejected efficiently by all mice, with or without perturbed MHC-I sensing 
(Table 3). All of this can be interpreted within a theoretical model, which will be presented in 
the next section. The increased rejection of MHC-I expressing tumour cells after inhibitory 
receptor blockade is more complex and requires additional interpretations to fit within the 
model; it will be discussed further below. 
Our results thus suggest that complete tolerance develops robustly even towards ligand 
deficient but otherwise normal host cells present only at low frequency under 
mosaic/chimaeric conditions. However, reactivity remains towards tumour cells of the 
corresponding MHC-I phenotype, which can be regarded as ‘’split tolerance’’ (i.e. different 
outcome for normal and tumour cells representing allele specific missing self). The model 
proposed here is that the host cells deficient in the additional MHC-I molecule (Dd), modulate 
responsiveness of NK cells expressing inhibitory receptors only against this ligand in the 
education process, i.e. the Dd- cells are critical and dominant tutors in the education process, 
even if they are in minority. The frequency dependent, quantitative educational effect, 
revealed when using MHC-I deficient spleen cells (ß2m-/- cells) or Dd- tumour cells (RMA) as 
targets, can then be interpreted in the following way (Figure 27). The responsiveness of NK 
cells is tuned during the span of several encounters with other host cells, and they must thus 
somehow continuously “keep the books” during the education process. The education 
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calibrates the responsiveness for each NK cell in response to the host environment in such a 
way that complete tolerance is ensured, i.e. no NK cell will exceed the ‘critical limit of net  
 
 
 
signalling required for killing’ in any encounter with such normal host cells. This is achieved 
by a reduction of responsiveness in certain NK cell subsets with inhibitory receptors for Dd 
molecules (but not for other MHC-I molecules) in DL6 mice, correlating with the number of 
Dd- cells in the environment. The reduced responsiveness cannot be read out with normal Dd- 
cells as targets, because all NK cells fall below the critical limit of net signalling required for 
killing in the context of those (Kb Db expressing) cells; complete tolerance is registered. The 
situation is different for tumour cells of the Dd- phenotype, because these are assumed to 
possess more activating ligands than normal cells, and also for MHC-I deficient normal cells, 
because these lack MHC-I ligands for other inhibitory NK cell receptors. These targets, 
therefore, fall within a window where the quantitative influence in the education process can 
be read out in different DL6 mice. However, RMA-S tumour cells with high expression of 
activating ligands and no MHC-I molecules, also fall outside of this window but in the 
opposite way compared to normal B6 spleen cells; these tumour targets are already highly 
sensitive to NK cells that have seen no Dd ligands (e.g. in B6 mice). Despite reduced general 
missing self responsiveness in DL6 mice, RMA-S cells are so sensitive that they are still 
efficiently killed.  
A similar interpretation can be applied to the results observed in the model based on 
inhibitory receptor blockade, although this experimental model did not allow us to correlate 
quantitative effects. In the paper where these results have been published, we proposed that 
the reduced inhibitory input caused by receptor blockade adapted the targeted NK cells ‘‘to 
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the signals received from normal cells in the environment; this can explain the reduced 
rejection of normal MHC class I- cells, as well as the robust tolerance observed against 
normal MHC class I–expressing cells after inhibitory receptor blockade’’ [222] While the 
adapted NK cells show reduced responsiveness towards MHC-I deficient healthy cells, this is 
not observed for the MHC-I expressing tumour cells, which lose the advantage of MHC-I  
 
 
 
expression in the effector-target interaction due to the receptor blockade. These are, therefore, 
killed more efficiently in the treated mice, which explains the difference observed when 
RMA tumour cells are used as targets in the inhibitory receptor blockade vs. the DL6 model 
(Table 3). 
There are thus, two opposing effects of the antibody treatment, the first on education (down-
tuning) and the second on the effector target interaction (increased killing) (Figure 28). The 
normal MHC class I deficient target cells reveal only the first effect, while the second effect 
dominates when MHC-I expressing RMA tumour cells are used. None of the effects are 
revealed with the normal MHC-I expressing cells in the in vivo rejection assay, since the 
down-tuning leads to complete tolerance towards these cells. The model proposes that the 
difference between MHC-I expressing tumour and normal cells is caused by higher 
expression of activating ligands on the former. Even if the targeted NK cells have been 
rendered less responsive, they still get sufficient activating net signalling when encountering 
the tumour cells, while the normal cells fall below this threshold. Finally, the RMA-S tumour 
cells also do not reveal any of the effects, because their impaired MHC expression and high 
Figure 27. Net signalling from the average NK cell encountering the target, as a function of 
increasing frequencies of Dd+ cells. 
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expression of activating ligands result in strong activating net signalling to NK cells, well 
above the critical threshold, in the presence as well as absence of inhibitory receptor 
blockade. Hence, strong rejection is observed in all situations (Table 3).  
This proposed interpretation suggests that the inhibitory receptor blockade also causes 
reduced NK cell responsiveness against the tumour cells, even if this is not revealed in the net 
effect observed in our experimental model based on RMA tumour cells. Other tumour cells 
may give different results, depending on their levels of activating ligands and other factors. 
 
 
 
Indeed, Carlsten et al. observed reduced in vitro responses to K562 tumour cells by NK cells 
from smouldering multiple myeloma patients, treated with “KIR blockade” antibodies [223]. 
In future development of inhibitory receptor blockade, it may, therefore, be important to 
develop strategies that maximizes the influence on the effector target interaction, and 
minimize the influence on the education process. This may be achieved by intermittent rather 
than continuous blockade, and by combination with other antibodies or cytokines that 
increase the responsiveness of NK cells.   
If the model above is correct, it is possible to infer clear and testable predictions concerning 
single cell features of NK cells in the DL6 mice, which link the frequency of Dd+ cells to the 
function of NK cells with inhibitory receptors for Dd. A schematic overview is presented in 
Table 4, where the three first columns represent NK cells with at least i) one receptor for Kb 
Db (but none for Dd), ii) one receptor for Kb Db and one for Dd, iii) one receptor for Dd (but 
none for Kb Db). Since the two first subsets possess receptors for ligands which are expressed 
by all cells in all the mice, there are only marginal predicted differences for the single cell 
responsiveness (e.g. CD107α/IFN-γ expression after stimulation with antibodies against 
activating receptors) between the mice. It is the third subset, which only possesses receptors 
Figure 28. Two potential effects of inhibitory receptor blockade, influencing the effector target 
interaction or education. 
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for Dd, that is critical and mainly responsible for the differences that we have observed in in 
vivo experiments.  
Any molecular determinants of MHC-I dependent education in these cells would also be 
predicted to correlate with the frequency of Dd expressing cells in the DL6 mice. So far, no 
such determinants have been identified. It is still unclear how education alters the signalling 
that sets the threshold for effector responsiveness. However, it appears that high expression of 
KLRG1 may be maintained as a downstream consequence of education. DNAM-I shows a 
similar pattern, except in NK cells that express NKG2A. It has recently been shown that 
DNAM-1 is turned on early during NK cell maturation in the bone marrow, and that the 
expression of this receptor gradually fades in all NKG2A- NK cells as they mature, except in 
those subsets possessing Ly49 receptors for host MHC-I molecules, i.e. the cells that become 
educated for high responsiveness (Wagner et al. Nature Comm, in press, 2017). It is, 
therefore, predicted that the expression of DNAM-1 as well as of KLRG1, should correlate 
with the frequency of Dd+ cells in DL6 mice.  
 
 
 
When testing these predictions, it may be important to bear in mind that despite the observed 
correlations between frequency of Dd+ cells and capacity for “allele specific” or “general” 
missing self reactivity, there was considerable variability in the rejection by individual DL6 
mice, across the entire range of mosaic MHC-I expression. We do not know the reason for 
this variability. It may be caused by factors unrelated to NK cell education, such as 
nutritional, hormonal, microbial factors. It cannot be excluded that the variability reflects 
actual differences in education, caused by additional receptor-ligand interactions, that are 
superimposed on or integrated with the effects of Dd molecules on inhibitory NK cell Ly49 
receptors. One possibility is that NK cells expressing the activating receptor Ly49D, known 
to bind to Dd, are also affected by the mosaic composition in the DL6 mice, but in the 
opposite manner to NK cells expressing inhibitory Dd receptors. This can actually be 
dissected experimentally by including staining for Ly49D expressing cells in scheme, 
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allowing gating on Ly49D single receptor expressing cells, as well as cells expressing Ly49A 
or Ly49G2 with or without Ly49D. 
 “Split tolerance” towards normal and tumour cells with the same MHC-I phenotype may be 
harnessed in immunotherapy, where heterogenous MHC-I expression occurs in the 
haematopoietic compartment, e.g. in haematopoietic transplantation or adoptive transfer of 
allogeneic NK cells. Transplantation of haploidentical or partially HLA-matched NK cells 
has been associated with reduced risk of GVHD and increased potential for GvL effects [135, 
234]. In other words, while exhibiting anti-tumour effects, these donor NK cells show 
tolerance towards normal cells expressing partially matching HLA, in the host. This is in line 
with the model presented here, since NK cells educated by KIR interactions with donor cells 
and lacking inhibitory KIRs for the recipient HLA ligands, will be tuned to tolerate normal 
recipient cells, but still kill tumour cells. Donor NK cells having inhibitory KIRs for the host 
HLA will also not attack normal recipient cells, but may kill tumour cells due to the same 
reason as mentioned above i.e. increased expression of activating ligands. To exploit this 
situation clinically, the gap in ‘split tolerance’ may be widened enough so that the anti-
tumour activity is increased while the reactivity towards normal cells may be reduced even 
further. It should finally be noted that NK cells lacking KIR for both donor and recipient 
HLA-ligands, i.e. non-MHC-I educated cells, may mediate anti-tumour activity under certain 
conditions. Evidence arguing for the efficacy of such cells has been provided in a study of 
patients receiving immunotherapy with IL-2 and histamine dihydrochloride (Bernson et al. 
Abstract, 16th Annual meeting of the Society for Natural Immunity NK2106, Taormina, 
Italy). 
An additional suggestion from the model is that one should transplant, transfer or strive to 
maintain as high frequency of donor haematopoietic NK cells as possible, in agreement with 
observations made in certain studies [146, 157, 235]. It has also been shown in a mouse 
chimaera study that tolerance may be induced in NK cells by either the haematopoietic or the 
non-haematopoietic tissue, with both situations favouring tolerance to the ‘ligand negative’ 
cell type in vivo [211]. However, it was observed that while tolerance induced by the 
haematopoietic tissue could be broken by infection or cytokine induced inflammation, this 
was not the case for that induced by the non-haematopoietic tissue, showing its stronger 
impact. This has been attributed to the presence of distinct educating mechanisms for NK 
cells by these tissue types. In a clinical situation, this may mean that reconstitution of a 
patient’s haematopoietic system with a donor graft lacking one or more HLA alleles may end 
up in breaking of tolerance towards the donor cells in case of an infection, and cause graft 
rejection. On the other hand, based on the model presented above and other studies, it may be 
recommended to select HSCT donors based on expression of several different KIR ligands, 
so that the NK cells without a KIR ligand in the host may exert their reactivity more 
effectively towards tumour cells. Quantitative and dynamic influences on NK cell education 
may prove important in the clinical use of NK cells, and this area should be exploited in 
further studies.  
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